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The goal of my dissertation work was to examine the systems biology of torsinA, a DYT1 dystoniaassociated protein, by using rodent model systems. TorsinA is a putative ATPase associated with a
variety of cellular activities (AAA+). Deletion of glutamic acid residue 302/303 in TOR1A is causally
associated with many cases of early-onset primary dystonia.
In our work, transient forebrain ischemia and sciatic nerve transection were used as central and peripheral
neural perturbations, respectively, to gain insight into the in vivo role(s) of torsinA. Moreover, transgenic
mouse models that overexpress either human mutant torsinA (hMT) or wild-type torsinA (hWT) were used
to analyze the behavioral, morphological, neurochemical, and brain metabolical consequences of
increased mutant torsinA burden.
After transient forebrain ischemia and sciatic nerve transection, torsinA expression levels were temporally
increased in both the central and peripheral nervous systems. In the hippocampus and dorsal root
ganglion, increased torsinA immunoreactivity was found located in neuronal populations such as
projection neurons, interneurons, and ganglion cells, and in glial elements such as reactive astrocytes and
satellite cells. These results suggest that torsinA participates in the response of neural tissue to central
and peripheral insults, and that limited recruitment of intact functional torsinA might contribute to the
onset of DYT1 dystonia in TOR1A ΔGAG mutation carriers. The striking induction of torsinA in astrocytes
and satellite cells points to the potential involvement of glial elements in the pathobiology of DYT1
dystonia.
In the DYT1 transgenic mice, mutant torsinA burden resulted in prolonged traversal times and more slips
on a raised-beam task; widened hind-base width; increased dopamine turnover in the striatum, and a shift
in brain energy demand from the basal ganglia to olivocerebellar pathways. However, no morphological
alterations were detected in the mutant mice with either light or electron microscopy. Our neurochemical
findings in DYT1 transgenic mice are compatible with previous postmortem neurochemical studies of
human DYT1 dystonia. Increased striatal dopamine turnover in torsinA mutant mice suggests that the
nigrostriatal pathway may be a site of functional neuropathology in DYT1 dystonia. The relatively
attenuated energy demand in basal ganglion output regions may be a manifestation of a primary
functional abnormality in the nigrostriatal system of DYT1 mutation carriers and the relatively elevated
energy demand in cerebellar cortex might be a compensatory response to dysfunction of the basal
ganglia.
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ABSTRACT
The goal of my dissertation work was to examine the systems biology of torsinA,
a DYT1 dystonia-associated protein, by using rodent model systems. TorsinA is a
putative ATPase associated with a variety of cellular activities (AAA+). Deletion of
glutamic acid residue 302/303 in TOR1A is causally associated with many cases of earlyonset primary dystonia.
In our work, transient forebrain ischemia and sciatic nerve transection were used
as central and peripheral neural perturbations, respectively, to gain insight into the in vivo
role(s) of torsinA. Moreover, transgenic mouse models that overexpress either human
mutant torsinA (hMT) or wild-type torsinA (hWT) were used to analyze the behavioral,
morphological, neurochemical, and brain metabolical consequences of increased mutant
torsinA burden.
After transient forebrain ischemia and sciatic nerve transection, torsinA
expression levels were temporally increased in both the central and peripheral nervous
systems. In the hippocampus and dorsal root ganglion, increased torsinA
immunoreactivity was found located in neuronal populations such as projection neurons,
interneurons, and ganglion cells, and in glial elements such as reactive astrocytes and
satellite cells. These results suggest that torsinA participates in the response of neural
tissue to central and peripheral insults, and that limited recruitment of intact functional
torsinA might contribute to the onset of DYT1 dystonia in TOR1A ΔGAG mutation
carriers. The striking induction of torsinA in astrocytes and satellite cells points to the
potential involvement of glial elements in the pathobiology of DYT1 dystonia.
In the DYT1 transgenic mice, mutant torsinA burden resulted in prolonged
traversal times and more slips on a raised-beam task; widened hind-base width; increased
dopamine turnover in the striatum, and a shift in brain energy demand from the basal
ganglia to olivocerebellar pathways. However, no morphological alterations were
detected in the mutant mice with either light or electron microscopy. Our neurochemical
findings in DYT1 transgenic mice are compatible with previous postmortem
neurochemical studies of human DYT1 dystonia. Increased striatal dopamine turnover in
torsinA mutant mice suggests that the nigrostriatal pathway may be a site of functional
neuropathology in DYT1 dystonia. The relatively attenuated energy demand in basal
ganglion output regions may be a manifestation of a primary functional abnormality in
the nigrostriatal system of DYT1 mutation carriers and the relatively elevated energy
demand in cerebellar cortex might be a compensatory response to dysfunction of the
basal ganglia.
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CHAPTER 1. INTRODUCTION
1.1

DYSTONIA

Dystonia has been defined by the Scientific Advisory Board of Dystonia Medical
Research Foundation as a syndrome of sustained involuntary muscle contractions; it
frequently causes twisting and repetitive movements, or abnormal movements and
postures (1988). It is generally accepted that dystonia is caused by a dysfunction of the
central nervous system with a resultant failure to “relax” muscles that are not required for
a particular motor act; that failure results in simultaneous contraction of opposing
muscles. Dystonia tends to improve with relaxation, sleep, or sensory tricks, and
intensify with action. Dystonia does not discriminate, and affects humankind of all ages,
both genders, and racial backgrounds. Dystonia affects over 300,000 people in North
America, and is the third most-common movement disorder after Parkinson’s disease and
tremor in the United States (Dystonia Medical Research Foundation).
Dystonia is a syndrome associated with a heterogeneous collection of genes and
disorders. Dystonia may be idiopathic (i.e., primary) or secondary to acquired insults to
the CNS and PNS such as trauma, metabolic disorders, and stroke. Dystonia may also be
associated with other neurological disorders such as Huntington's disease, Parkinson's
disease, Lesch–Nyhan syndrome, and ataxia telangiectasia. Primary dystonia can be
classified by age of onset as early- or late-onset dystonia, and by topographic distribution
as focal, segmental, multifocal, and generalized (Nemeth, 2002; Tarsy and Simon, 2006).
The severity of the dystonic symptoms may show a modest variability during the
course of each day. Dystonia may be associated with pain, functional disability, and a
significantly impaired quality of life. In general, the primary dystonias are not associated
with intellectual impairment or shortened lifespan. At present, there are no permanent
cures for dystonia. However, a variety of treatments is available to improve the
symptoms. Treatment options include dopamine-depleting agents such as tetrabenazine,
anticholinergics, benzodiazepines, botulinum toxin injections, deep-brain stimulation,
and physical therapy (Klein and Ozelius, 2002; Tarsy and Simon, 2006).
1.1.1 Classification
The heterogeneity of dystonia has prompted the development of several
classification schemes. Classically, dystonia can be clinically classified in three ways: by
the age of symptom onset as early-onset and adult-onset; by topographic distribution as
focal, segmental, multifocal, generalized, and hemidystonia; and etiologically as primary,
dystonia-plus, heredodegenerative, and secondary; and genetically according to the
monogenic gene mutation (Fahn et al., 1998; de Carvalho Aguiar and Ozelius, 2002;
Tarsy and Simon, 2006).
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Based on data from patients with primary torsion dystonia (Bressman et al., 1998;
2000), if symptoms begin before the age of 26, dystonia is classified as early-onset
dystonia, whereas, if symptoms begin after 26 years of age, dystonia is classified as lateonset dystonia. The age of onset is very important for prognosis and counseling. Earlyonset dystonia can be rapidly progressive,; it often begins in a leg and commonly spreads
to involve other parts of the body. In contrast, late-onset dystonia often remains focallydistributed.
Dystonia can also be classified following the topographic distribution of the
affected region. The term “focal” is applied when only a single body part is affected.
More specific terms are also used to describe focal dystonias which affect a single body
part, such as blepharospasm (eyes), cervical dystonia (neck, also called torticollis), or
laryngeal dystonia (larynx, also called spasmodic dysphonia). When two or more
contiguous body parts are involved, it is called segmental dystonia; for example, cranial–
cervical dystonia, crural dystonia, or brachial dystonia. In multifocal dystonia, two or
more noncontiguous body parts are involved. Generalized dystonia refers to dystonia,
which involves the legs, or one leg and the trunk, in addition to one other area of the
body. The term “hemidystonia” is used to denote involvement of the arm and leg on the
same side of the body.
Etiologically, dystonia is classified as primary, dystonia-plus, heredodegenerative
and secondary. Primary dystonia includes syndromes in which dystonia is the sole
phenotypic manifestation with the exception that tremor can be present as well. The
“dystonia-plus” category includes syndromes with other neurological manifestations in
which no evidence of neurodegeneration has been identified, such as dopa-responsive
dystonia, and myoclonus-dystonia. Heredodegenerative dystonia includes syndromes in
which dystonia occurs in the setting of neurodegenerative diseases such as Parkinson’s
disease, multiple system atrophy, and Huntington’s disease. Secondary dystonia includes
syndromes in which dystonia is the manifestation of a structural or metabolic abnormality
of the brain or peripheral nervous system. Secondary dystonia can be associated with
strokes, brain tumors, neurotoxins, infectious (e.g., human immunodeficiency virus), and
demyelinating disorders (e.g., multiple sclerosis, and neoplasic diseases).
1.1.2

Genetics and Dystonia

Over 16 forms of hereditary dystonia (DYT1-16; Table 1-1) have been described
to date (Klein and Ozelius, 2002; Nemeth, 2002; Breakefield et al., 2008). Within those
16 hereditary disorders included in the DYT classification scheme, only DYT1, DYT2,
DYT4, DYT6, DYT7, and DYT13 are genuine subtypes of primary dystonia. DYT1,
DYT2, DYT4, and DYT6 often begin focally prior to generalization. However, DYT7
and DYT13 typically persist as focal dystonias. DYT5, DYT11, DYT12, DYT14,
DYT15, and DYT16 belong to dystonia-plus family, because additional neurological
features are present in addition to dystonia. For example, DYT5, DYT12, and DYT16
frequently exhibit Parkinsonism, and DYT11 and DYT15 often present with myoclonus.
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Table 1-1. Molecular classification of dystonia.

128100

Chromosomal
location
9q32-34

TorsinA (TOR1A)

Dystonia 2; autosomal recessive

224500

Unknown

Unknown

DYT3

Dystonia 3; X-linked dystoniaparkinsonism; ‘lubag’

314250

Xq13.1

DYT4

Dystonia 4; “non-DYT1”

128101

DYT5
GCH1

Dystonia 5; dopa-responsive
dystonia-parkinsonism

DYT5
TH

Locus

Designation

OMIM

DYT1

Dystonia 1; early-onset primary
dystonia; Oppenheim's dystonia

DYT2

Gene

Mode of
inheritance
AD, incomplete
penetrance

Clinical characteristics

Reference

Early-onset generalized, usually starts in a
limb

Ozelius et al.,
1997

AR

Early-onset, generalized or segmental

Zlotogora, 2004

TATA-binding
protein-associated
factor-1 (TAF1)

XR

Only discriped in individuals from
Philipines; usually male; Segmental or
generalized dystonia with parkinsonism
unresponsive to L-dopa; progressive
neurodegenerative syndrome

Makino et al.,
2007

Unknown

Unknown

AD

Single large Australian family; laryngeal
and cervical dystonia

Ahmad et al.,
1993

128230

14q22.1q22.2

GTP
cyclohydrolase I
(GCH1)

AD, incomplete
penetrance

Dystonia with concurrent or subsequent
parkinsonism, diurnal worsening of
symptoms and a dramatic response to Ldopa

Ichinose et al.,
1994

Segawa syndrome

191290

11p15.5

Tyrosine
hydroxylase

AR

Same as DYT5/GCH1

Ludecke et al.,
1995

DYT6

Dystonia 6; adolescent-onset of
mixed type

602629

8p21-q22

Unknown

AD

Adolescent-onset, mostly segmental PTD,
rarely generalizes

Almasy et al.,
1997

DYT7

Dystonia 7; adult-onset focal

602124

18p11.3

Unknown

AD, incomplete
penetrance

Adult-onset focal dystonia (torticollis,
writer’s cramp, dysphonia, or
blepharospasm)

Leube et al.,
1996

DYT8

Dystonia 8; paroxysmal dystonic
choreoathetosis; paroxysmal
non-kinesigenic dyskinesia

118800

2q35

Myofibrillogenesis
regulator-1 (M
R1)

AD, incomplete
penetrance

Attacks of dystonia/choreoathetosis,
precipitated by stress, fatigue, alcohol, and
chocolate

DYT9

Dystonia 9; paroxysmal
choreoathetosis with episodic
ataxia and spasticity

601042

1p21-p13.3

Unknown

AD

Attacks of dystonia, parasthesias, double
vision, precipitated by exercise, stress, and
alcohol; spastic paraplegia between attacks

Rainier et al.,
2004;
Djarmati et al.,
2005
Auburger et al.,
1996

DYT10

Dystonia 10; paroxysmal
kinesigenic choreoathetosis

128200

16p11.2-q12.1

Unknown

AD, incomplete
penetrance

Attacks of dystonia/choreoathetosis,
brought on by sudden movements; respond
to anticonvulsant therapy
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Tomita et al.,
1999

Table 1-1. (Continued).
Locus

Designation

OMIM

Chromosoma
l location
7q21
11q23

Gene
Epsilonsarcoglycan
(SGCE)

Mode of
inheritance
AD, incomplete
penetrance

Clinical characteristics

Reference

Rapid, jerk-like movements, responsive to
alcohol; combined with variable degrees of
dystonia

Zimprich et al.,
2001
Kramer et al.,
1999;
de Carvalho
Aguiar et al.,
2004
Valente et al.,
2001

DYT11

Dystonia 11; myoclonusdystonia

159900

DYT12

Dystonia 12; rapid-onset
dystonia-parkinsonism

128235

19q12-q13.2

Alpha-3 subunit of
the N,K-ATPase
(ATP1A3)

AD, incomplete
penetrance

Dystonia or parkinsonism developing over
hours or weeks

DYT13

Dystonia 13;
multifocal/segmental dystonia

607671

1p36.32p36.13

Unknown

AD, incomplete
penetrance

Focal or segmental dystonia with onset
either in the cranial-cervical region or in
the upper limbs; mild course

DYT15

Dystonia 15; alcohol-responsive
myoclonic dystonia

607488

18p11

Unknown

AD, incomplete
penetrance

Alcohol-responsive myoclonic dystonia
characterized mainly by jerky movements
of the upper limbs, hands, and axial
muscles

Grimes et al.,
2002

DYT16

Dystonia 16; young-onset
dystonia-parkinsonism

612067

2q31.3

Protein kinase,
interferoninducible doublestranded RNAdependent
activator
(PRKRA)

AR

Progressive, generalised, early-onset
dystonia with axial muscle involvement,
oromandibular (sardonic smile), laryngeal
dystonia and, in some cases, parkinsonian
features, and do not respond to levodopa
therapy

Camargos et al.,
2008

Notes: AD, autosomal dominant; AR, autosomal recessive; PTD, primary torsion dystonia; XR, X-linked recessive.
Modified with permission. Klein C, Ozelius LJ (2002) Dystonia: clinical features, genetics, and treatment. Curr Opin Neurol
15(4): 491-497.
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DYT3 is classified as a heredodegenerative dystonia, because post-mortem histological
analysis has shown neuronal loss and astrocytosis in the striatum. DYT8, DYT9, and
DYT10 are paroxysmal dystonias that are triggered by stress, drugs, exercise, or sudden
movements.
Most of the hereditary dystonias are inherited in the autosomal dominant (AD)
mode with incomplete penetrance. The low penetrance of many of the hereditary
dystonias suggests that other genetic traits or environment factors might play a role in
their onset.
To date, eight genes, mutations of which are responsible for the onset of inherited
form of dystonia, have been identified: (1) DYT1 (Oppenheim's dystonia, OMIM
128100) due to mutation in TOR1A that encodes torsinA (Ozelius et al., 1997); (2) DYT3
(Lubag, OMIM 314250) due to insertion mutations in TATA-binding protein-associated
factor 1 (TAF1) located on chromosome Xq13.1 (Makino et al., 2007); (3) DYT5 (doparesponsive dystonia, OMIM 128230) autosomal dominant form caused by mutations in
the gene for guanosine triphosphate cyclohydrolase I (GCH1)(Nygaard et al., 1993;
Ichinose et al., 1994), (4) autosomal recessive form caused by a mutation in tyrosine
hydroxylase (TH)(Lüdecke et al., 1995); (5) DYT8 (paroxysmal non-kinesigenic
dyskinesia, OMIM 118800) secondary to missense mutations in the myofibrillogenesis
regulator 1 (MR-1)(Rainier et al., 2004; Djarmati et al., 2005); (6) DYT11 (myoclonusdystonia syndrome, OMIM 159900) secondary to mutations that lead to a truncation of
the membrane glycoprotein ε-sarcoglycan (SGCE)(Zimprich et al., 2001); (7) DYT12
(rapid-onset dystonia-parkinsonism, OMIM 128235) caused by mutations in the gene that
encodes the α-3 subunit of the Na+/K+ ATPase (ATP1A3)(de Carvalho Aguiar et al.,
2004); and (8) DYT16 (young-onset dystonia-parkinsonism, OMIM 612067) due to a
mutation in the stress-response gene PRKRA, which encodes the protein kinase,
interferon-inducible double-stranded RNA-dependent activator (Camargos et al., 2008).
1.2

DYT1 DYSTONIA

Ozelius and colleagues (1997) identified gene TOR1A in chromosome 9q32-9q34.
A 3-bp deletion (GAG) in Exon 5 of TOR1A is associated with the majority of the cases
of early-onset primary generalized dystonia. Some cases are clearly familial, whereas
others appear sporadic. TOR1A is expressed ubiquitously in human tissues, and encodes
a protein named torsinA. The GAG deletion mutation results in the loss of a glutamic
acid in the carboxy terminus of torsinA (Ozelius et al., 1997; 1999). DYT1 dystonia is an
uncommon disorder. The prevalence of the DYT1 GAG deletion has been reported to be
0.3 to 0.5 per 100,000 in the general population of Europe. However, in Ashkenazi Jews,
the frequency is much higher, around 1 per 2,000 to 6,000 (Kamm, 2006).
DYT1 dystonia is a severe hereditary form of early-onset primary generalized
dystonia. It is an autosomal dominant disease with less than 40% penetrance. The onset
of dystonia usually appears between 5 to 26 years of age. Onset before 4 years or after
28 years is rare. Generally, the symptoms usually develop first in the legs as focal limb
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dystonia, and typically generalize within 5 years (Bressman et al., 1998; 2000).
However, variable phenotypic expressions have also been reported. Grundmann and
colleagues (2003) screened a moderately large cohort of German dystonia patients with a
GAG deletion in TOR1A and evaluated the dystonic phenotypic expression in DYT1
carriers, and found that 6 out of 256 patients were DYT1 haplotype carriers. Two of the
patients expressed the classic phenotype of early-onset primary generalized dystonia, two
expressed multifocal dystonia, and the remaining two subjects presented with writer's
cramp, and showed only slight progression over several years.
The pathophysiology of DYT1 dystonia is not well understood. Postmortem
neuropathological studies of brains from subjects with primary dystonia failed to reveal
any consistent evidence of neuronal loss, inflammation, or neurodegeneration. These
findings suggest that functional and/or ultrastructural abnormalities, rather than
neurodegeneration, underlie dystonic symptoms (Rostasy et al., 2003).
1.2.1 Neuropathology in DYT1 Dystonia
Zweig (1988) have examined brain tissues from two cases of early-onset primary
generalized dystonia. They found neurofibrillary tangles in several brainstem nuclei such
as locus ceruleus (LC), substantia nigra pars compacta (SNpc), pedunculopontine nucleus
(PPN), and dorsal raphe (RMg) nucleus, and a mild neuronal loss within the LC in one
case. However, they did not reveal consistent findings in the other case. Hornykiewicz
and colleagues (1986) also reported that they did not find important histological changes
in the basal ganglia, cerebral cortex, and some of the tested brainstem nuclei in two cases
of early-onset primary generalized dystonia. Rostasy and colleagues (2003) carefully
examined striatum, cerebellum, hippocampal formation, and SN of post-mortem brain
tissues from three manifesting DYT1 carriers, three non-DYT1 dystonic patients, and
eleven controls. They did not reveal any disease-specific evidence of gliosis and
apoptosis. They did not detect cytoplasmic inclusion bodies in neurons in all brain
tissues tested from dystonia patients. However, they noticed larger nigral dopaminergic
neurons in all dystonia brains, and more closely spaced neurons in SN in manifesting
DYT1 carriers. McNaught and colleagues (2004) later reported evidence of perinuclear
inclusion bodies in some of the neurons in PPN, the cuneiform nucleus and
periaqueductal gray (PAG), but not in the SNpc, striatum, hippocampus, and neocortex in
four manifesting DYT1 carriers tested. These multifarious findings suggest that
functional and/or ultrastructural abnormalities rather than neurodegeneration underlie
DYT1 dystonia.
1.2.2 Neurochemical Studies in DYT1 Dystonia
Several groups have studied the neurochemical changes in DYT1 dystonia and
have generated diverse findings. Hornykiewicz and colleagues (1986) reported
norepinephrine (NE) and serotonin (5-HT) level changes in several brain regions in two
cases of early-onset primary generalized dystonia, with decreased dopamine (DA) levels
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in striatum in one case. Furukawa and colleagues (2000) noticed the attenuated striatal
DA levels (50% to 54% of control means) in the rostral putamen and caudate nucleus in
one case of DYT1 dystonia. Augood and colleagues (2002) reported significantly
increased striatal 3,4-dihydroxyphenylacetic acid (DOPAC)/DA, and a trend towards
reduced striatal D1 and D2 receptor binding in three cases of DYT1 dystonia compared to
three controls. Asanuma and colleagues (2005) studied nine non-manifesting DYT1
carriers and found that attenuated D2 receptor binding (85% of control) was a trait of the
DYT1 genotype. These various investigations indicate that imbalances in nigrostriatal
neurochemical signaling may contribute to disease manifestations in DTY1 dystonia.
1.2.3

Neuroimaging Studies in DYT1 Dystonia

Neuroimaging studies of DYT1 dystonia include metabolic and structural
approaches. In the metabolic studies, hyperactivity has been reported in several brain
regions in DYT1 carriers. Eidelberg and colleagues (1998) identified brain metabolic
activity changes in DYT1 carriers with [18F] fluorodeoxyglucose (FDG) and positron
emission tomography (PET). Those changes include genotype-related hyperactivity in
lentiform nuclei, cerebellum, and supplementary motor areas (SMA), and syndromerelated hyperactivity in the midbrain, cerebellum, and thalamus. Ghilardi and colleague
(2003) reported brain functional abnormalities during task performance by using H215O
PET. They found an increased activation in the left premotor cortex and right SMA, and
an attenuated activation in the posterior medial cerebellum in DYT1 carriers during
motor performance as well as an increased activation in the left ventral prefrontal cortex
and lateral cerebellum in DYT1 carriers during sequence learning. Carbon and
colleagues (2004a) reported syndrome-related hyperactivity in the presupplementary
motor area (Brodmann area [BA] 6) and parietal association cortices bilaterally (BA
40/7), and genotype-related hyperactivity in the putamen, anterior cingulate (BA 24/32),
and cerebellar hemispheres in DYT1 carriers with [18F] FDG PET.
In neurostructural studies, Carbon and colleagues (2004b; 2008a) noticed
decreased fractional anisotropy (FA) in several brain regions in DYT1 carriers with
diffusion tensor magnetic resonance imaging (DTI), that is a marker of axonal
disintegrity. Those decreased fractional anisotropy included syndrome-related decrease
in the left dorsal pontine brainstem and in the white matter of the sensorimotor cortex
bilaterally, and genotype-related decrease in the white matter of the sensorimotor cortex
in DYT1 carriers.
In aggregate, work to date in humans indicates DYT1 dystonia is due to
functional and/or ultrastructural abnormalities of the brain rather than
neurodegeneration..
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1.3

TORSINA

TorsinA is the protein encoded by TOR1A. The dystonia-related GAG deletion
results in the loss of a glutamic acid in the carboxy terminal (Ozelius et al., 1997; 1999).
The molecular and cellular functions of torsinA are essential but not well understood.
From the amino acid sequence, torsinA belongs to ATPases associated with a variety of
cellular activities (AAA+) superfamily (Ozelius et al., 1997; 1999). TorsinA possesses
an N-terminal signal sequence, a single AAA+ module, and two biochemically-confirmed
glycosylation sites (Figure 1-1). The AAA+ module contains four conserved motifs: a
Walker A motif that regulates nucleotide binding; a Walker B motif that is crucial for
ATPase activity; a sensor 1 that is critical for nucleotide hydrolysis; and sensor 2 that is
essential for nucleotide binding and hydrolysis(Ozelius et al., 1997; Neuwald et al., 1999;
Ozelius et al., 1999; Joshi et al., 2003; Kamm et al., 2004; Hanson and Whiteheart, 2005;
Callan et al., 2007). Unlike the other three motifs, which are very conserved and play
similar functions between AAA+ proteins, sensor 2 determines the specificity of the
protein (Joshi et al., 2003). Sensor 2 is also a very important domain to regulate subunit
and/or substrate conformational changes. It’s a function-determined domain for AAA+
proteins because AAA+ proteins assemble into hexamers to function, and the most
essential function is to regulate conformational changes of the substrates (Neuwald et al.,
1999; Joshi et al., 2003; Hanson and Whiteheart, 2005). Members of the AAA+ family
function as molecular chaperones for protein quality control (protein complex assembly,
operation, disassembly, protein folding, unfolding, and degradation), membrane fusion
and vesicular transport, and cytoskeletal regulation (Neuwald et al., 1999; Vale, 2000;
Ogura and Wilkinson, 2001), all of these activities might provide insight regarding the
function of torsinA.
TorsinA is an endoplasmic reticulum (ER)-resident glycoprotein (Hewett et al.,
2003; Kuner et al., 2003; Liu et al., 2003; Callan et al., 2007). Strong torsinAimmunoreactivity (IR) is located diffusely in the cytoplasm of neurons that extends
throughout neurites to synapses (Konakova et al., 2001; Konakova and Pulst, 2001;
Augood et al., 2003; Kuner et al., 2003; Kamm et al., 2004). When overexpressed in
cultured cells, mutant torsinA is enriched at the nuclear envelope (Goodchild and Dauer,
2004; Naismith et al., 2004).
In normal brain, torsinA-IR is widely distributed in all anatomical structures with
intense IR detected in pyramidal neurons in neocortex, cholinergic interneurons in
striatum, pyramidal neurons in hippocampus, motor neurons in the trigeminal nuclei, and
dopaminergic neurons in the SNpc (Shashidharan et al., 2000a; Konakova and Pulst,
2001; Xiao et al., 2004). In rat brain, torsinA-IR is present in the cytoplasm, dendrites
and axons but not in nuclei (Xiao et al., 2004).
TorsinA might function as a chaperone for unfolded or degraded proteins, and
might facilitate movement of polytopic proteins to the cell surface (Torres et al., 2004).
TorsinA has been localized to protein aggregations such as Lewy bodies in Parkinson's
disease brain and inclusion bodies in trinucleotide repeat diseases, and its overexpression
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Figure 1-1. Alignment of human, rat, and mouse torsinA amino-acid sequences.
Sequence disparities are shaded. The N-terminus of torsinA contains a 20-aa hydrophobic
signal sequence (underlined) , a AAA+ module, two biochemically-confirmed
glycosylation sites (N143, N158; solid triangle) and six conserved cysteine residues
(C44, C49, C50, C162, C280, C319; asterisk). The AAA+ module includes four
conserved motifs (walkerA, walkerB, sensor1, sensor2; bold italic and underlined). The
site of GAG (E) deletion is presented bold and marked as solid circle. The possible
phosphorylation sites for protein kinase C (PKC) and casein kinase 2(CK2) are boxed.
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facilitates the clearance of those protein aggregates (Shashidharan et al., 2000b; Sharma
et al., 2001; McLean et al., 2002; Caldwell et al., 2003; Walker et al., 2003). TorsinA
was found to interact with kinesin light chain 1 (KLC1) in a yeast two-hybrid study
(Kamm et al., 2004). KLC1 is part of the heterotetrameric motor protein kinesin-I, and is
thought to be involved in cargo binding and/or kinesin-I activity regulation (Kamal and
Goldstein, 2002). TorsinA was also shown to modulate the cellular trafficking of the
dopamine transporter (Torres et al., 2004; Cao et al., 2005), as well as other membranebound proteins, including G protein-coupled receptors, transporters, and ion channels
(Torres et al., 2004). In addition, overexpression of torsinA facilitates the clearance of
another dystonia-related protein, SGCE, by the ubiquitin proteosome system, and protects
PC12 cells against a variety of cellular insults, including serum deprivation and oxidative
stress (Kuner et al., 2003; Shashidharan et al., 2004; Esapa et al., 2007). Similarly,
overexpression of torsinA protects dopamine neurons from oxidative stress in C. elegans
(Cao et al., 2005). In a mammalian model, torsinA expression was up-regulated after
oxidative stress in dopamine neurons in vivo (Kuner et al., 2004).
The chaperone function(s) of torsinA might include maintenance of cellular
polarity and regulation of neurite extension by interactions with the cytoskeleton.
Support for this hypothesis derives from several fronts. First, in vitro research has shown
that torsinA-IR was localized to filopodia in cultured cells, whereas torsinA-IR has been
detected in synapses in brain tissues (Konakova et al., 2001; Konakova and Pulst, 2001;
Augood et al., 2003; Kamm et al., 2004). TorsinA was also confirmed to localize with
microtubules and to co-immunoprecipitate with microtubule-associated protein tau
(Ferrari-Toninelli et al., 2003; 2004; Hewett et al., 2006). Next, overexpression of
mutant torsinA inhibited neurite extension; however, attenuation of wild-type torsinA
facilitated neurite extension in SH-SY5Y cells (Ferrari-Toninelli et al., 2004; Hewett et
al., 2006). TorsinA is critical for postnatal neurodevelopment. The expression of torsinA
is striking in the prenatal and early postnatal period, with a most intense expression in
cerebellum and cholinergic interneurons in striatum at postnatal day 14 (Xiao et al.,
2004), which is a period of intense cellular migration, neurite extension, and
synaptogenesis. TorsinA knock-out and homozygous ΔGAG knock-in mice die shortly
after birth (Goodchild et al., 2005). In aggregate, these studies suggest that torsinA might
play an important role to regulate and maintain an anatomically or structurally precise
neurite orientation.
TorsinA might also play a role to maintain nuclear envelope architecture and
positioning. First of all, mutant torsinA tends to accumulate in the lumen of the nuclear
envelope; however, wild-type torsinA is predisposed to stay in the lumen of ER
(Goodchild and Dauer, 2005; Hewett et al., 2006; 2007; Nery et al., 2007). Next, torsinA
interacts with lamin-associated polypeptide 1 (LAP1) in the nuclear envelope and
lumenal domain-like LAP1 (LULL1) in the endoplasmic reticulum (Goodchild and
Dauer, 2005). In a more recent work, torsinA was found to localize to a protein complex
that contained several cytoskeletal complexes including motor protein kinesin light chain,
LAP1, LULL1, plectin, and nesprin (Hewett et al., 2006; Nery et al., 2007). Plectin is an
anchoring protein that associates with all three major components of the cytoskeleton for
cross-linking (Liu et al., 1996). Nesprin is the outer nuclear membrane protein that
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interacts with cytoskeleton elements or the linker protein plectin (Wilhelmsen et al.,
2005). The coordinated function of cytoskeletal and nuclear envelope proteins is very
important for nuclear positioning and cell migration. TorsinA knock-out and
homozygous ΔGAG knock-in mice develop blebs in the nuclear envelope, which
protrude from the inner nuclear membrane (Goodchild et al., 2005). Furthermore, OOC5, a torsinA homologue in C. elegans, plays an essential role in PAR protein localization.
The PAR family of proteins is essential for cellular polarity and partition establishment,
and localization. Mutations of ooc-5 result in an abnormal nuclear rotation and polarity
in C. elegans embryos (Basham and Rose, 1999; 2001).
Recent studies point out a critical role for torsinA in regulating protein secretion
and synaptic vesicle recycling. Hewett and colleagues (2007; 2008) reported that protein
secretion processes were compromised in fibroblasts from DYT1 patients, and that
attenuation of mutant torsinA expression restored protein secretion in DYT1 fibroblasts.
In closely related work, Granata and colleagues (2008) found that an overexpression of
wild-type torsinA attenuated synaptic vesicle recycling, whereas an overexpression of
ΔE-torsinA intensified synaptic vesicle recycling at the expense of specificity.
TorsinA has a highly homologous family member torsinB, which is encoded by
TOR1B located adjacent to TOR1A on human chromosome 9q34 (Hewett et al., 2004).
TorsinB shares 61% amino acid identity with torsinA. Like torsinA, torsinB also harbors
a AAA+ domain along with several glycosylation and phosphorylation sites (Hewett et
al., 2004; O'Farrell et al., 2004). TorsinB is expressed in the neurons and is enriched at
the nuclear envelope (Hewett et al., 2004; O'Farrell et al., 2004). In
immunoprecipitation studies, torsinB was found to be associated with torsinA (Hewett et
al., 2004), which suggested the possibility that torsinA and torsinB interact at a functional
level. However, the developmental expression patterns of these two proteins are
divergent with striking expression of torsinA during the prenatal and early postnatal
periods, and prominent expression of torsinB during late the postnatal period and
adulthood (Vasudevan et al., 2006). In summary, although torsinA and torsinB exhibit
important structural similarities, torsinB can not completely compensate for the loss of
torsinA since DYT1 knock-out mice die shortly after birth (Goodchild et al., 2005).
Although various studies have been done to disclose the function of torsinA, and a
heterogeneous function of torsinA has been reported, the systems biology of torsinA, and
the causal effect of mutant torsinA to dystonia, are still unclear. Genetically modified
animal models are useful tools to investigate the contributing effects of mutant torsinA to
the onset of DYT1 dystonia and to open the door for future studies.
1.4

ANIMAL MODELS OF DYT1 DYSTONIA

Several murine models of DYT1 dystonia have been developed, and characterized
to various degrees (Dang et al., 2005; Goodchild et al., 2005; Sharma et al., 2005;
Shashidharan et al., 2005; Dang et al., 2006; Grundmann et al., 2007; Yokoi et al., 2008).
These models include DYT1 knock-out (Goodchild et al., 2005), cortex-specific DYT1
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knock-out (Yokoi et al., 2008), torsinA knock-down (Dang et al., 2006), transgenic
overexpression of mutant and wild-type torsinA (Sharma et al., 2005; Shashidharan et al.,
2005; Grundmann et al., 2007), and DYT1 ΔGAG knock-in (Dang et al., 2005;
Goodchild et al., 2005) mouse models. In the DYT1 ΔGAG knock-in mouse model, a
GAA trinucleotide deletion was made to mimic the GAG deletion in human DYT1
mutation, which was supposed to encode one of the glutamic acids at the position
corresponding to human E302/303. In addition, the expression of the DYT1 ΔGAG
transcript was confirmed with RT-PCR and sequencing.
Whereas common features exist among some of these models, inconsistent
findings have been noticed (Table 1-2). In addition, a comprehensive behavioral,
neurochemical, and brain metabolical evaluation are needed for all the models. TOR1A
knock-out and homozygous TOR1A ΔGAG knock-in are embryonically or early
postnatally lethal (Dang et al., 2005; Goodchild et al., 2005); morphological studies of
these mice revealed neuronal-specific nuclear envelope vesicles, which appeared to
derive from the inner nuclear membrane. Dang and colleagues (2005) evaluated the
behavioral, morphological, and neurochemical features of heterozygous ΔGAG knock-in
mice. They discovered abnormal motor behaviors in 6-month old male heterozygous
ΔGAG knock-in mice, including horizontal hyperactivity in the open-field test, increased
slips on the beam-walking test, and increased overlap in the foot-print analysis. They
also noticed ubiquitin- and torsinA-positive aggregates in neurons of the pontine nuclei
and attenuated striatal homovanillic acid (HVA) levels in male heterozygous ΔGAG
knock-in mice. In the DYT1 knock-down model, motor deficits such as horizontal
hyperactivity and increased slips on the beam-walking test were also noticed with
reduced striatal DOPAC in a neurochemical study (Dang et al., 2006). These findings
suggest that torsinA is an essential protein for postnatal survival, and that ΔGAG is a loss
of function mutation. In a more recent study, similar motor deficits were reported in a
cortex-specific DYT1 knock-out model (Yokoi et al., 2008). The authors suggest that
loss of torsinA in the cerebral cortex alone is sufficient to mimic behavioral deficits
noticed in heterozygous ΔGAG knock-in and DYT1 knock-down mice.
Transgenic models of DYT1 dystonia have been developed by Sharma et al.
(2005), Shashidharan et al. (2005), and Grundmann et al. (2007). Shashidharan and
colleagues (2005) reported that 40% of their ΔGAG transgenic mice displayed dystonic
movements of the limbs with self-clasping, circling behavior, and hyperactivity. They
also found ubiquitin- and torsinA-positive inclusions in the PPN, pons, and PAG, and a
decreased striatal DOPAC/DA ratio in ΔGAG transgenic mice with a decreased striatal
DA only in manifesting transgenic mice. The ΔGAG transgenic mice developed by
Sharma and colleagues (2005) showed a reduced ability to learn motor skills in an
accelerating rotarod paradigm at six months of age, as well as abnormal dopaminergic D2
receptor responses in striatal cholinergic interneurons (Pisani et al., 2006) and an
attenuated amphetamine-induced striatal DA release (Balcioglu et al., 2007). In a more
recent study, Grundmann and colleagues (2007) generated another DYT1 transgenic
model, in which torsinA expression was driven by a murine prion protein promoter.
They found behavioral, morphological, and neurochemical abnormalities in ΔGAG
transgenic mice (GAG3, a hΔGAG transgenic line) and wild-type transgenic mice
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Table 1-2. Murine DYT1 models.
Model

Molecular construct

Morphology

Behavior

Neurochemistry

DYT1 transgenic
(Shashidharan et al.,
2005)

7.1 kb fragment from the
pNSE-Ex4 vector containing the
neuron specific enolase promoter,
human mutant (ΔGAG) torsinAcDNA and SV40 polyA signal

ubiquitin- and torsinA-IR
perinuclear aggregates
and/or inclusion in the
pedunculopontine nucleus,
pons & periaqueductal
gray

40% of transgenic mice from
each line displayed dystonic
movements of the limbs with
self-clasping, circling
behavior, &
hyperactivity

↓ striatal DA in
transgenic animals that
exhibited an abnormal
behavioral phenotype, ↓
striatal DOPAC/DA ratio
in all transgenic mice

DYT1 transgenic
(Sharma et al., 2005)

human wildtype (hWT) or mutant
(ΔGAG) torsinA-cDNAs were
inserted into pcDNA3.1 under the
human cytomegalovirus immediate
early promoter.

no torsinA-positive
inclusions or increased
staining around the nuclear
envelope (NE)

reduced ability to learn motor
skills in an accelerating
rotarod paradigm

↓ amphetamine-induced
striatal extracellular DA
levels

DYT1 knock-in
(Dang et al., 2005)

Exon 5 in the targeting vector
construct carries a GAA deletion at
codon 302. The PGKNeoSTOP
cassette with a false translation
signal, splice donor site, and an
additional poly(A) tail was inserted
into intron 4.

ubiquitin- and torsinAcontaining aggregates in
pontine nuclei of male
DTY1 knock-in mice

deficient performance on the
beam-walking test, open-field
hyperactivity

↓ striatal HVA

DYT1 knock-out
(Goodchild et al.,
2005)

Exons 2-4 of Tor1a were replaced
by a cassette containing Neo and
IRES-tau LacZ sequences

vesicles within the
neuronal NE that appear to
derive from the inner
nuclear membrane

DYT1 knock-in
(Goodchild et al.,
2005)

Exon 5 in the targeting construct
carries a GAG deletion. Neo
cassette was inserted into intron 4
of Tor1a.

homozygotes exhibit
vesicles within the
neuronal NE that appear to
derive from the inner
nuclear membrane
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Table 1-2. (Continued).
Model

Molecular construct

TOR1A knock-down
(Dang et al., 2006)

PGKNeoSTOP cassette with a false
translation signal, splice donor site,
and an additional poly(A) tail was
inserted into intron 4 of Tor1a and
recombination occurred 5' to an
Exon 5 GAA deletion

DYT1 transgenic
(Grundmann et al.,
2007)

human wild-type (hWT) and mutant
(hΔGAG) torsinA-cDNAs were
inserted into pBluescript II SKvector under the 3.4 kb fragment of
the murine prion protein promoter
and tagged C-terminally with V5His

Cerebral Cortexspecific DYT1
Knock-out
(Yokoi et al., 2008)

Exons 3-4 of Tor1a were deleted by
Emx1-cre in cerebral cortex

Morphology

Behavior

Neurochemistry

horizontal hyperactivity,
↑ slips on a beam-walking
test

↓ striatal DOPAC

inclusion-like formation in
brainstem nuclei , torsinAIR localized to the NE, and
NE abnormalities in both
hWT and hΔGAG mice

hWT mice: hypoactivity,
short stride length, prolonged
traversal times on beam
walking
hΔGAG mice: hyperactive,
defects on rotarod testing

hWT mice: ↓ striatal
DA, 5-HT and 5-HIAA;
↓ brainstem HVA
hΔGAG mice: ↑
brainstem DOPAC, 5-HT
and 5-HIAA

reduction of torsinA-IR in
the cortical layers

↓ hind base width in male
↑ slips on a beam-walking
open-field hyperactivity
more revolutions
or circling behaviors

No change
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(WT24, a hWT transgenic line). The GAG3 mice showed deficient performance on
rotarod testing and hyperactivity in open-field tests as well as inclusion bodies in
brainstem nuclei and nuclear envelope vesicles in brainstem and striatum.
Neurochemical analysis also revealed elevated levels of DOPAC, 5-HT, and 5hydroxyindoleacetic acid (5-HIAA) in the brainstem of GAG3 mice. The behavioral
abnormalities noticed in WT24 mice included prolonged traversal times on beamwalking, shorter stride length on foot-print analysis, and hypoactivity on open-field tests.
WT24 mice also exhibited inclusion bodies in brainstem nuclei and nuclear envelope
vesicles in brainstem and striatum. In contrast to GAG3 mice, neurochemical studies
revealed reductions in striatal DA, 5-HT, 5-HIAA, and brainstem HVA in WT24 mice.
1.5

EXOGENOUS FACTORS

1.5.1

Perturbations and Secondary Dystonia

Trauma to the central nervous system (CNS) and periphery are established causes
of secondary dystonia (Schott, 1985; Lee et al., 1994; Hollinger and Burgunder, 2000;
Hummel and Lucking, 2001; LeDoux and Brady, 2003). For example, Sankhla and
colleagues (1998) reported that 27 out of 160 subjects with oromandibular dystonia had a
history of facial trauma, oromandibular surgery, or a dental procedure. A previous
history of head or face trauma with loss of consciousness occurred in 7.3% of cranial
dystonia patients and 7.5% of extracranial dystonia patients in a case control study by
Defazio et al. (1998). The study by Defazio and colleagues also revealed that 12% of
cervical dystonia patients had a history of neck or trunk trauma, and 25% blepharospasm
patients had anterior-segment ocular diseases.
Ischemic stroke is one of the more common causes of secondary dystonia
(Jankovic and Van der Linden, 1988; Krystkowiak et al., 1998; Alarcon et al., 2004).
Ischemic strokes that affected the striatum, globus pallidus, and thalamus have been
clinically associated with the appearance of dystonic symptoms (Krystkowiak et al.,
1998; LeDoux and Brady, 2003). Alarcon and colleagues (2004) did a cohort study on
stroke and reported that 16 out of 1500 patients developed dystonia up to one year after
either ischemic or hemorrhagic stroke.
Prescription drugs and neurotoxins are other well-known causes of secondary
dystonia (Liu et al., 1992; He et al., 1995; van Harten et al., 1998; van Harten et al., 1999;
Johnson et al., 2000). Neuroleptic drugs can precipitate acute dystonic reactions. The
risk for neuroleptic-induced dystonia is modified by risk factors such as age, gender, and
concomitant medications (Remington et al., 1990; Khanna et al., 1992; van Harten et al.,
1999). In a study, cocaine was reported to be a risk factor for neuroleptic-induced
dystonia (van Harten et al., 1998). A neurotoxin, 3-nitropropionic acid (3-NPA),
produced by the fungus Arthrinium, often present in moldy sugarcane, was also noted to
induce delayed dystonia (Liu et al., 1992; He et al., 1995; Johnson et al., 2000).
Analyses of the secondary dystonias suggest that dopaminergic systems contribute to the
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pathophysiology of this movement disorder in a subset of cases. In many patients,
lesions or insults involve widespread insults to the nervous system.
1.5.2

Inciting Factors of Primary Dystonia

Environmental factors are clearly associated with the development of primary
adult-onset dystonias. Repetitive highly skilled tasks such as writing or playing a string
instrument significantly increase the risk of developing task-specific focal hand dystonia
(Chen and Hallett, 1998). Interestingly, scoliosis is a risk factor of cervical dystonia,
possibly via compensatory alterations in head postures (Defazio et al., 2003).
Alternatively, scoliosis could simply be the manifestation of axial dystonia, which
precedes the development of adult-onset cervical dystonia. Measles, mumps, or upper
respiratory tract infections appear to be associated with the onset of spasmodic dysphonia
(Schweinfurth et al., 2002). Defazio and colleagues (1999) also reported that prior head
or face trauma with loss of consciousness was a risk factor for the spread of
blepharospasm. Another group also reported that, in a cohort study of young onset
primary cervical dystonia, 17.1% had been exposed to prior neck injury or surgery
(Koukouni et al., 2007). Thus, acute trauma and chronic repetitive use strain might
precipitate dystonia in genetically predisposed individuals.
1.6

SIGNIFICANCE OF THE STUDY

Although the association of the GAG deletion in T0R1A and mutant torsinA with
generalized dystonia has been known for over a decade, most work with torsinA has been
done in cultured cells. The systems biology of torsinA has been largely ignored.
Because the DYT1 dystonia is penetrated in only 30-40% of carriers (Ozelius et al.,
1997), genetic modifiers and/or environmental factors might trigger the onset of DYT1
dystonia in genetically predisposed individuals. Relatively common perturbations (e.g.,
severe febrile illnesses, perinatal hypoxia, trauma, and intense sensorimotor training),
which may affect either the CNS or PNS, occur with variable frequency and severity
among DYT1 mutation carriers, and might trigger the onset of dystonic symptoms in
perturbation-exposed DYT1 carriers. To understand the systems biology of torsinA after
central and peripheral insults, we examined torsinA expression following transient
forebrain ischemia and sciatic nerve transection, respectively. Our results, as described
in Chapter 2, provide evidence that torsinA participates in the response of neural tissue to
central and peripheral insults. By extrapolation, lower perturbation-induced expression
of functional torsinA might possibly contribute to the appearance of DYT1 dystonia in
mutation carriers.
The behavioral, pathological, and neurochemical consequences of mutant torsinA
have not been vigorously explored in the CNS. For example, postmortem
neuropathological and neurochemical studies have been limited to a few human DYT1
brains, and have not been confirmed in replicate studies (Augood et al., 2002; Rostasy et
al., 2003). Due to a limited availability of human postmortem tissues, genetically
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modified animal models provide useful models to investigate and confirm findings in
human patients and to open the door for future studies. In Chapter 3, transgenic mouse
models that overexpress either human wild-type torsinA (hWT) or human mutant torsinA
(hMT; two lines hMT1 and hMT2) were employed for behavioral, morphological,
neurochemical, and metabolic examination of the DYT1 carrier state. This work is
important because it identifies important regions and pathways that might be critical to
the systems pathophysiology of DYT1 dystonia. On the other hand, some of the findings
reported in Chapter 3 might simply be compensatory responses to the burden of mutant
torsinA and the DYT1 genotype. In either case, the data presented in Chapter 3 might
provide important insights into the underpinnings of DYT1 dystonia.
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CHAPTER 2. TORSINA EXPRESSION AFTER NEURAL PERTURBATIONS
TO THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS *
2.1

INTRODUCTION

TorsinA is an ER-resident glycoprotein, in which a single glutamic acid deletion
in amino acid 302/303 is associated with the development of early-onset primary
generalized dystonia (Ozelius et al., 1997). The molecular and cellular functions of
torsinA are essential for survial but are not well-understood. The primary amino acid
sequence of torsinA placed it within the AAA+ superfamily (Ozelius et al., 1997; 1999)
and, as such, torsinA might function as a molecular chaperone.
A variety of studies have provided evidence that torsinA is a chaperone for
protein quality control and protein degradation. TorsinA has been found localized with
protein aggregations such as Lewy bodies and polyglutamine-containing neuronal
inclusions in postmortem human brain (Shashidharan et al., 2000b; Sharma et al., 2001;
Walker et al., 2003). Overexpression of torsinA suppressed the formation of protein
aggregates in cellular and C. elegans models (McLean et al., 2002; Caldwell et al., 2003).
Overexpression of torsinA was also found to facilitate clearance of another dystoniarelated protein, SGCE, by the ubiquitin-proteosome system (Esapa et al., 2007).
Moreover, torsinA expression was up-regulated after oxidative stress in PC12 cells and
dopaminergic neurons in the substantia nigra pars compacta (Hewett et al., 2003; Kuner
et al., 2004). Overexpression of torsinA protects COS-1 and PC12 cells against a variety
of cellular insults (Kuner et al., 2003; Shashidharan et al., 2004). Similarly,
overexpression of torsinA protects dopaminergic neurons from oxidative stress in C.
elegans (Cao et al., 2005).
TorsinA might also modulate the cellular trafficking of polytopic proteins such as
dopamine transporter (Torres et al., 2004; Cao et al., 2005), as well as other membranebound proteins, including G protein-coupled receptors, transporters, and ion channels
(Torres et al., 2004). TorsinA might, however, play more than one role in cells. In
particular, several lines of evidence suggest that torsinA might be part of the molecular
machinery required to maintain nuclear envelope architecture and position, and to
regulate neurite extension, protein secretion, and synaptic vesicle transport (FerrariToninelli et al., 2004; Goodchild and Dauer, 2005; Hewett et al., 2006; 2007; Granata et
al., 2008; Hewett et al., 2008).
When overexpressed in cells, mutant torsinA is concentrated at the nuclear
envelope and tends to form perinuclear inclusion bodies (Hewett et al., 2000; Bragg et al.,
2004). Mutant torsinA has reduced ATPase activity (Konakova and Pulst, 2005; Pham et
*

Permission to reproduce by International Brain Research Organization. Zhao Y, Xiao J,
Ueda M, Wang Y, Hines M, Nowak TS Jr, LeDoux MS (2008) Glial elements contribute
to stress-induced torsinA expression in the CNS and peripheral nervous system.
Neuroscience. 155: 439-453.
18

al., 2006). Accordingly, loss of normal function might be one consequence of the
missing glutamic acid residue in torsinA (McLean et al., 2002; Caldwell et al., 2003;
Hewett et al., 2006; 2007; Granata et al., 2008; Hewett et al., 2008). However, the most
deleterious result of mutant torsinA might be its dominant negative effects on wild-type
torsinA (Torres et al., 2004; Cao et al., 2005; Hewett et al., 2008).
Because penetration of the DYT1 dystonia is only 30-40% (Ozelius et al., 1997),
environmental factors might contribute to the onset of dystonia in genetically predisposed
individuals. Trauma to the PNS and CNS (Schott, 1985; Lee et al., 1994; Sankhla et al.,
1998; Hollinger and Burgunder, 2000; Hummel and Lucking, 2001), drugs (Remington et
al., 1990; Khanna et al., 1992; van Harten et al., 1998; van Harten et al., 1999),
neurotoxins (Liu et al., 1992; He et al., 1995; Johnson et al., 2000), and stroke
(Krystkowiak et al., 1998; Alarcon et al., 2004) are known causes of secondary dystonia.
Environmental factors also correlate with the onset of primary adult-onset dystonias
(Chen and Hallett, 1998; Schweinfurth et al., 2002; Defazio et al., 2003). Because DYT1
mutation carriers demonstrate variable phenotypes from primary generalized dystonia to
adult-onset focal dystonia, DYT1 dystonia and sporadic adult-onset dystonia may share
common environmental risk factors (Leube et al., 1999; Grundmann et al., 2003). Based
on this information, subclinical perturbations (e.g., fever, hypoxia, trauma, and intense
sensorimotor training) to the CNS or PNS, which often occur in variable combinations
and severity in DYT1 mutation carriers, might trigger the onset of early-onset generalized
dystonia in perturbation-exposed carriers (Treves and Korczyn, 1986). Despite these
important clinical associations, little is known about the expression and localization of
torsinA after neural perturbations in vivo. Our study evaluated the temporal and spatial
expression of torsinA in response to central and peripheral nervous system insults in
models of transient forebrain ischemia and sciatic nerve transection, respectively.
Insufficient response of functional torsinA to environment insults might contribute to the
onset of DYT1 dystonia in DYT1 mutation carriers.
2.2

METHODS

2.2.1

Animals

All experiments were performed in accordance with the National Institutes of
Health’s Guide for the Care and Use of Laboratory Animals and with approval of the
Institutional Animal Care and Use Committee. Wistar rats (Hilltop Lab Animals, Inc.,
Scottdale, PA, USA) were used for transient forebrain ischemia because the effects of 4vessel occlusion (4-VO) have been well characterized in animals of this source and strain
(Pulsinelli and Brierley, 1979; Ueda and Nowak, 2005). The sciatic nerve transections
were performed in Sprague-Dawley rats (Harlan, Indianapolis, IN, USA).
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2.2.2

Transient Forebrain Ischemia

Adult male Wistar rats (250 - 300 g) were subjected to transient 4-VO ischemia
(Pulsinelli and Brierley, 1979) with direct current (DC) potential monitoring as
previously described (Ueda and Nowak, 2005). In brief, surgical procedures were carried
out under general inhalational anesthesia with 1 - 2% halothane in 70% N2 and 30% O2.
The vertebral arteries were electrocauterized at the first cervical segment, and Silastic
occluding devices were placed around the common carotid arteries. On the following
day, rats were re-anesthetized and placed in a stereotaxic frame. Epidural and rectal
temperatures were monitored and maintained at 37°C. Hippocampal DC potentials were
recorded with glass microelectrodes. The carotid occluding devices were tightened to
produce cerebral ischemia, as verified by 10 - 20 mV shifts in DC potential. All
hemispheres included in these studies exhibited ischemic depolarizations of 7 - 9 min
duration in hippocampus, previously shown to produce consistent loss of CA1 neurons
(Ueda and Nowak, 2005). After release of occlusions, scalp incisions were closed, and
rats were allowed to recover from anesthesia. Control rats underwent sham surgical
procedures that included vertebral artery cauterization and electrode placement without
carotid occlusion.
Brain tissues for RNA extraction and in situ hybridization were obtained at five
post-ischemic survival intervals (6 hr, 24 hr, 7 d, 14 d, and 21 d), whereas tissues for
immunocytochemistry were collected at three post-ischemic survival intervals (24 hr, 7 d,
and 14 d). Preparations from three ischemic and three sham control rats were obtained at
each survival interval.
For RNA extraction and in situ hybridization, rats were anesthetized with 5%
halothane prior to decapitation. Brains were rapidly removed from the cranial vault and
were sectioned in the mid-sagittal plane. For in situ hybridization, hemispheres were
frozen in isopentane (-40 °C), sectioned parasagittally at 16 μm, and stored at -80 °C in
sealed slide boxes with desiccant capsules. For RNA extraction, cerebellum, striatum,
thalamus, hippocampus, and cerebral cortex were dissected from the hemisphere, and
were homogenized in RNAwizTM (Ambion, Austin, TX, USA) on ice within 2 - 3 min
after decapitation.
For immunocytochemistry, rats were overdosed with pentobarbital (100 mg/kg,
intraperitoneally [IP]) prior to transcardiac perfusion with heparinized saline, and 4%
paraformaldehyde/0.1 M phosphate buffer (PB). Brains were post-fixed for 2 hrs,
blocked, and incubated in a cryoprotectant solution (30% sucrose/0.1 M PB, pH 7.4) for
at least 48 hrs. Blocks were sectioned at 20 μm, and were collected on SuperFrost®-Plus
glass slides (Fisher Scientific, Pittsburgh, PA, USA).
2.2.3

Sciatic Nerve Transection

Three-month old male Sprague-Dawley rats (250-300 g) were subjected to left
sciatic nerve transection under ketamine/xylazine (87/13 mg/kg, IP) anesthesia. The rat
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sciatic nerve was readily identified in the posterior thigh between the vastus lateralis and
caput vertebralis muscles. In each rat, the left sciatic nerve was completely transected
except for the medial epineurium, which was left intact to allow for apposition of the cut
ends to facilitate axonal regeneration. Wounds were closed, and animals were allowed to
recover from anesthesia in individual cages. Four age-, weight- and gender-matched nonsurgical control rats were only subjected to anesthesia. Four surgical rats were employed
at each of five post-transection intervals (24 hr, 3 d, 7 d, 14 d, and 28 d). Three rats in
each group were utilized for RNA extraction, and one was used for immunocytochemical
examination of the dorsal root ganglia (DRG).
For RNA extraction, rats were overdosed with pentobarbital (100 mg/kg, IP) prior
to transcardiac perfusion with saline and RNAlater (Ambion) as described in LeDoux et
al. (2006). The vertebral column was sharply dissected from the remainder of the
carcass, and was placed in a 50 ml conical tube that contained RNAlater. The vertebral
column was kept moist with RNAlater, while the right and left lumbar (L3-L6) DRG
were microsurgically isolated and collected into separate pools for subsequent RNA
extraction.
For immunocytochemistry, rats were overdosed with pentobarbital (100 mg/kg,
IP) prior to transcardiac perfusion with heparinized saline and 4% paraformaldehyde/0.1
M PB. The vertebral column was dissected and kept moist with fixative, while the right
and left lumbar (L4-L5) DRG were isolated and collected into separate vials. DRG were
post-fixed for an additional 2 hr, and transferred to a cryoprotectant solution for at least
48 hr. DRGs were sectioned at 15 μm with a cryostat, and were collected on
SuperFrost®-Plus glass slides.
2.2.4 Relative Quantitative Real-time RT-PCR (QRT-PCR)
Relative levels of torsinA mRNA were established in all brain and DRG tissues
collected for QRT-PCR. The QRT-PCR detection of torsinA mRNA levels in brain
regions was performed by Dr. Jianfeng Xiao in Dr. LeDoux’s lab. In brief, total RNA
was extracted with RNAwizTM. RNA purity and concentration were analyzed with a
NanoDrop® spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
DNA was removed with DNA-freeTM (Ambion). Reverse transcription was performed
with RETROscriptTM (Ambion) kit with 200 ng total RNA as template. The reaction mix
was incubated at 44 °C for 1 hr, and at 92 °C for 10 min. QRT-PCR was performed with
Taqman® probes (Applied Biosystems, Foster City, CA, USA) for the target gene
(torsinA) and endogenous controls (18S rRNA for brain tissues and GAPDH for DRG).
Primer and probe sequences are described in Table 2-1. Of note, technical triplicates
were performed on each sample, and median values were used for subsequent analyses.
Differential expression of torsinA was determined with the comparative threshold
cycle (CT) method. In particular, the expression levels of torsinA transcript in the
ischemic and sham brains at each post-ischemic interval were calculated relative to the
mean CT value for the sham controls at the corresponding time points. A two-factor
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Table 2-1. Probe and primers used for QRT-PCR, and primers used to generate in
situ hybridization probes.
Name

Sequence (5’→3’)

QF1

ggccgtgtcggtcttcaata

QR1

atagccacgggactgcatct

QPro

6-FAMcaagaacagtggcttctggcacagc
a-TAMRA

TOR1AF

aagcggagcctcagccgtga

TOR1AR
TOR1SF

gataatacgactcactatagggccac
aaacaggtgtacata
gataatacgactcactatagggaagc
ggagcctcagccgtga

TOR1SR

ccacaaacaggtgtacata

TOR2AF

aaggaccaattacagatgtggat

TOR2AR
TOR2SF

gataatacgactcactatagggccag
ggcgtgctccatgtct
gataatacgactcactatagggaag
gaccaattacagatgtggat

TOR2SR

ccagggcgtgctccatgtct

TOR3AF

acaagaacagtggcttctggca

TOR3AR
TOR3SF

gataatacgactcactatagggaaca
cagtcttgcagccctt
gataatacgactcactatagggacaa
gaacagtggcttctggca

TOR3SR

aacacagtcttgcagccctt

ActinAF

agcaagagaggcatcctga

ActinAR
ActinSF
ActinSR

gataatacgactcactatagggacaa
cacagcctggatggcta
gataatacgactcactatagggagca
agagaggcatcctga
acaacacagcctggatggcta

Locus
NM_153303
743– 762 nt
NM_153303
893– 874 nt
NM_153303
764– 789 nt
NM_153303
180– 199 nt
NM_153303
423– 405 nt
NM_153303
180– 199 nt
NM_153303
423– 405 nt
NM_153303
465– 487 nt
NM_153303
744– 725 nt
NM_153303
465– 487 nt
NM_153303
744– 725 nt
NM_153303
763– 784 nt
NM_153303
991– 972 nt
NM_153303
763– 784 nt
NM_153303
991– 972 nt
NM_031144
178–196 nt
NM_031144
421–401 nt
NM_031144
178–196 nt
NM_031144
421–401 nt
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Usage

Product
(bp)

RT-PCR
RT-PCR

151 (with
QF1)

RT-PCR probe
antisense probe 1
antisense probe 1

244 (with
1AF)

sense probe 1
sense probe 1

244 (with
1SF)

antisense probe 2
antisense probe 2

280 (with
2AF)

sense probe 2
sense probe 2

280 (with
2SF)

antisense probe 3
antisense probe 3

229 (with
2AF)

sense probe 3
sense probe 3
β-actin antisense
probe
β-actin antisense
probe
β-actin sense
probe
β-actin sense
probe

229 (with
2SF)
244 (with
ActinAF)
244 (with
ActinSF)

(treatment and post-ischemic interval) analysis of variance (ANOVA) was used for
statistical analysis with SAS (SAS Institute, Cary, NC, USA).
For relative quantitative analysis of torsinA mRNA in the DRG, expression levels
were calculated in reference to the mean CT value for all right and left (L3-L6) DRG
from the three non-surgical control rats. One-factor ANOVAs were used for independent
analysis of data from the right and left DRG. Single degree-of-freedom post-hoc
contrasts were limited to comparisons between individual post-surgical time points and
ipsilateral control DRG. Analysis of the ipsilateral (left) DRG at 28 d was limited to two
rats bscause poor-quality RNA was obtained from the third animal in this group.
2.2.5

In situ Hybridization

Radiolabeled (35S-UTP) complementary RNA (cRNA) probes were used to
localize torsinA transcript in cryostat sections of rat brain. Primer pair sequences to
make the radioactive probes are described in Table 2-1. The detailed protocol is
provided in Xiao et al. (2004). In brief, probes were made by in vitro transcription with
T7 RNA polymerase (Ambion). After fixation, acetylation, and dehydration through a
graded series of ethanol, slides were incubated overnight in the hybridization buffer with
radioactive probes (final concentration - 3 x 104 cpm/µl). After treatment with RNase A
(Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 30 min followed by a high stringency
wash at 60 °C for 1 h, slides were dehydrated and exposed to Kodak Biomax MR Film
along with 14C Microscale™ autoradiography standards (RPA504, Amersham
Biosciences, Piscataway, NJ, USA) for 5 days. Each sheet of film was exposed to paired
ischemia and sham microscopic slides. Autoradiographic images were acquired in the
transmission mode (ScanMaker 9800 XL, Microtek, Carson, CA, USA), and were
imported into ImageJ (Java version of NIH Image, http://rsb.info.nih.gov/ij/) for region of
interest (ROI) quantification of radioactivity. Optical density (O.D.) was calibrated to the
set of autoradiography standards to generate measures of radioactivity (nCi/g tissue) for
each ROI. Hippocampal ROIs include internal and external blades of the dentate granule
cell layer (iDG, eDG), four regions of stratum pyramidale that encompassed CA1 (Z1C,
Z2C) and CA3 (Z3C, Z4C), and stratum oriens (SO), stratum radiatum (SR) and stratum
lacunosum-moleculare (SLM) of the CA1 region. Signal was acquired from 15 pixels (3
x 5 rectangle) in the center of each ROI, from seven sections per animal, and the average
was expressed relative to the mean obtained from sham sections hybridized in each of the
experimental runs. Two-factor (treatment and post-ischemic interval) ANOVA was used
for statistical analysis of relative radioactivity within each ROI.
2.2.6 Immunocytochemistry
The primary and secondary antibodies used for immunocytochemical studies are
listed in Table 2-2. Cryostat brain and DRG sections were collected in eight and six
series, respectively. One series of slides was air-dried overnight, and was stained with
cresyl violet (brain) or hematoxylin and eosin (DRG). The other series were processed
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Table 2-2. Primary and secondary antibodies.
Antibody name

Type

Target

Concentration

Source

TA1

rabbit
polyclonal

torsinA

1:500

D-M2A8

mouse
monoclonal

torsinA

1:300

Antisomatostatin

rabbit
polyclonal

somatostatin

1:250

Parv-19

mouse
monoclonal
mouse
monoclonal
mouse
monoclonal
mouse
monoclonal

parvalbumin

1:1000

GFAP

1:500

Dr. Vijaya
Ramesh, Harvard
Medical School
Dr. Vijaya
Ramesh, Harvard
Medical School
Chemicon
International,
Temecula, CA,
USA
Sigma, St. Louis,
MO, USA
Chemicon

microglia

1:500

Chemicon

vimentin

1:10

mouse
monoclonal
horse
polyclonal

synaptophysin

1:100

Abcam,
Cambridge, MA,
USA
Abcam

mouse IgG
(H+L)

1:500

goat
polyclonal
donkey
polyclonal

rabbit IgG
(H+L)
mouse IgG
(H+L)

1:500

donkey
polyclonal

rabbit IgG
(H+L)

1:250

donkey
polyclonal

mouse IgG
(H+L)

1:250

donkey
polyclonal

rabbit IgG
(H+L)

1:250

GA5
OX-42
V9
SY38
biotinylated
horse antimouse
biotinylated goat
anti-rabbit
Cy2-tagged
donkey antimouse
Cy2-tagged
donkey antirabbit
rhodamine redX-tagged
donkey antimouse
rhodamine redX-tagged
donkey antirabbit
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1:250

Vector,
Burlingame, CA,
USA
Vector
Jackson
ImmunoResearch
Laboratories
Jackson
ImmunoResearch
Laboratories
Jackson
ImmunoResearch
Laboratories
Jackson
ImmunoResearch
Laboratories

for immunohistochemical detection of torsinA and biomarkers for hippocampal
interneurons (somatostatin and parvalbumin), astrocytes (glial fibrillary acidic protein
[GFAP]) microglia (OX-42), intermediate filaments (vimentin), and synaptic vesicles
(synaptophysin). Anatomically equivalent sections from animals that represented each of
the three post-ischemic survival intervals and corresponding sham controls were
processed simultaneously. Ipsilateral and contralateral DRG sections from all postsurgical intervals were processed as a group.
For peroxidase-based detection of torsinA, sections were first incubated in the
quenching buffer (10% methanol and 3% H2O2 in 0.02 M phosphate-buffered saline
[PBS]) for 5 min. Sections were blocked and permeabilized in PBS that contained 2%
nonfat dry milk and 0.3% Triton X-100 (Sigma). Sections were incubated overnight with
primary antibody diluted in PBS with 3% normal serum (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) and 0.1% Triton X-100. Sections were incubated
with biotinylated secondary antibody diluted in PBS with 2% normal serum and 0.1%
Triton X-100 for 4 hrs, peroxidase-labeled streptavidin (Vector Laboratories,
Burlingame, CA, USA) for 1 hr, and nickel-intensified diaminobenzidine (Vector
Laboratories) for visualization. Between each step, slides were thoroughly rinsed with
PBS. After the final rinse, slides were air-dried overnight, dehydrated, cleared, and
coverslipped with Permount (Fisher Scientific).
Double-label fluorescent immunocytochemistry was used to examine the
relationships between torsinA and cell-type specific biomarkers (Table 2-2). Two
primary antibodies that recognized torsinA were used in these studies: a rabbit
polyclonal, TA1, and a mouse monoclonal, D-M2AB. When TA1 was employed, Cy2or rhodamine red-X (RRX)-tagged donkey anti-rabbit secondary antibodies (Jackson
ImmunoResearch Laboratories) were used to visualize torsinA-IR. With D-M2A8,
biotinylated horse anti-mouse was used as a secondary antibody followed by Cy2-tagged
streptavidin (Jackson ImmunoResearch Laboratories). Slides were thoroughly rinsed,
dehydrated, cleared, and coverslipped with 1,3-diethyl-8-phenylxanthine (DPX; SigmaAldrich) mounting medium. Sections were visualized with epifluorescence (Leica
DM6000, Leica Microsystems Inc, Bannockburn, IL, USA) and confocal laser-scanning
(Bio-Rad Laboratories, Hercules, CA, USA) microscopes. For consistency of
illustration, all torsinA-IR was transferred to the RGB green channel, and other
biomarker-IR to the RGB red channel within Adobe Photoshop (San Jose, CA, USA).
2.3

RESULTS

2.3.1

TorsinA Transcript Was Up-regulated after Transient Forebrain Ischemia

QRT-PCR was performed to evaluate the spatial and temporal expression of
torsinA mRNA after transient forebrain ischemia, with 18S rRNA as an endogenous
control. The efficiencies of torsinA (1.74) and 18S rRNA (1.75) amplification were
practically identical; the slope of ΔCT versus log10 ng total RNA was 0.054. The CT
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values associated with torsinA and 18S rRNA amplification showed strong linear
relationships with log10 ng total RNA (torsinA: R2=0.978; 18S rRNA: R2=0.990).
Up-regulation of torsinA mRNA was not detected at the 6 hr post-ischemic
interval. However, torsinA mRNA levels were significantly elevated within 24 hr after
ischemia in all regions tested (Figure 2-1). Transcript levels remained elevated at 7 days
in all regions, and declined toward sham values by 14 d in striatum, thalamus, and cortex,
and by 21 d in cerebellum and hippocampus. In hippocampus and cerebellum, there were
strong overall effects of ischemia (hippocampus [F1, 20 = 21.63, P = 0.0002], cerebellum
[F1, 20 = 13.12, P = 0.0017]), post-ischemic interval (hippocampus [F4, 20 = 5.24, P =
0.0047], cerebellum [F4, 20 = 4.17, P = 0.0129]), and their interaction (hippocampus [F4, 20
= 5.34, P = 0.0043], cerebellum [F4, 20 = 4.48, P = 0.0095]) on torsinA mRNA levels
(Figure 2-1). In these two regions, increased expression of torsinA transcript was
present at 24 hr, 7 d, and 14 d but not at 6 hr or 21 d. In the other three regions
examined, the effects of ischemia were also considerable (striatum [F1, 20 = 13.96, P =
0.0013], thalamus [F1, 20 = 8.43, P = 0.0088], and cerebral cortex [F1, 20 = 17.72, P =
0.0004]), although there were no significant effects of post-ischemic interval and the
ischemia x post-ischemic interval interaction on the relative levels of torsinA transcript.
As seen in Figure 2-1, individual contrasts between the ischemia and sham groups were
significant (P < 0.05) in all regions tested at the 24 hr and 7 d post-ischemic intervals
and, additionally, in cerebellum and hippocampus at the 14 d post-ischemic interval. The
degree of torsinA mRNA up-regulation was greatest in ischemic cerebral cortex and
hippocampus (> 3-fold). TorsinA mRNA up-regulation in thalamus and striatum was
also substantial (> 2-fold compared to control).
The distribution of torsinA mRNA expression determined by in situ hybridization
was consistent with its generalized expression in major neuron populations. And the
torsinA hybridization signal was not grossly impacted following ischemia (Figure 2-2).
The decline in signal, evident in the hippocampal CA1 pyramidal layer at longer postischemic intervals, was consistent with the loss of these neurons. In addition, a more
diffuse increase in torsinA hybridization was apparent in hippocampal neuropil at 7 and
14 days, as further supported by quantitative analyses. Among the nine hippocampal
ROIs analyzed, SLM (F1, 16 = 18.13, P = 0.0006) and iDG (F1, 16 = 6.88, P = 0.0185)
showed the largest overall effects of ischemia on relative torsinA radioactivity (Figure
2-3). The ischemia x post-ischemic interval interaction was also significant in iDG (F3, 16
= 4.89, P = 0.0134) and SLM (F3, 16 = 5.71, P = 0.0074). In SLM, for example, relative
torsinA radioactivity was only increased at the 7 d post-ischemic interval. In Z1C and
Z2C, the effects of post-ischemic interval (F1, 16 = 13.03, P = 0.0001 and F1, 16 = 16.86, P
= 0.0001, respectively) and the ischemia x post-ischemic interval interaction (F3, 16 =
10.32, P = 0.0005; F3, 16 = 17.33, P = 0.0001) were highly significant due to the increased
signal in post-ischemic tissue at 24 hr and decreased signal at 7 d. Other noteworthy
findings were the effects of ischemia in SR (F1, 16 = 9.26, P = 0.0077) and the ischemia x
post-ischemic interval interaction in eDG (F1, 16 = 8.37, P = 0.0014). Individual contrasts
between the ischemia and sham groups showed that relative torsinA radioactivity first
became elevated at the 24 hr post-ischemic interval in iDG, eDG, Z2C, and Z1C (P<
0.05, for all). At the 7 d post-ischemic interval, relative torsinA radioactivity was

26

Figure 2-1. QRT-PCR analysis of regional torsinA expression after transient
forebrain ischemia.
TorsinA transcript levels in each brain region are expressed relative to the mean CT value
for the sham controls at each time point. A significant increase in torsinA transcript was
observed in all regions at 24 hr and 7 d post-ischemic intervals, and persisted in
cerebellum and hippocampus at 14 d. Results are expressed as the mean ± SEM (*, P <
0.05 for the difference between ischemic and sham groups at each interval).
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Figure 2-2. In situ hybridization of torsinA.
Representative parasagittal sections are illustrated for a sham control and at indicated
post-ischemic intervals, together with higher-magnification images of the corresponding
hippocampus. Evident changes included a decrease in torsinA expression in the CA1
pyramidal cell layer at late post-ischemic intervals, accompanied by elevated signal in
neighboring neuropil (arrow). Scale bars indicate 5 mm for whole-brain images and 500
µm for hippocampal images. The upper panel identifies ROIs subjected to further
quantitative analysis (see Figure 2-3) including the internal and external blades of the
dentate granule cell layer (iDG, eDG); four regions of stratum pyramidale that encompass
CA1 (Z1C, Z2C) and CA3 (Z3C, Z4C); and stratum oriens (SO), stratum radiatum (SR)
and stratum lacunosum-moleculare (SLM) of the CA1 region.
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Figure 2-3. Quantitative in situ hybridization analysis of hippocampal torsinA
transcript levels.
TorsinA hybridization was determined in the ROIs indicated in Figure 2-3, and were
expressed relative to the mean value for sham sections hybridized in each experimental
run. A slight but significant increase in torsinA transcript was observed in dentate
granule cells (iDG and eDG) and CA1 neurons (Z1C and Z2C) at 24 hr after ischemia.
Expression in the CA1 pyramidal layer decreased at later intervals, accompanied by
increased expression in SR, SLM, and SO at 7 d. Results are expressed as the mean ±
SEM (*, P < 0.05 for the difference between ischemic and sham groups at each postischemic interval)

29

significantly up-regulated in SO, SR and SLM (P < 0.05, for all), and down-regulated in
Z2C and Z1C (P < 0.05, for both). By 21 d post-ischemia, torsinA hybridization returned
toward sham values in all regions except Z2C.
Given the possible relationship of SNpc functional abnormalities to the
pathophysiology of DYT1 dystonia, SNpc torsinA transcript levels were evaluated with
quantitative in situ hybridization. As seen in Figure 2-4, there was a significant effect of
ischemia, post-ischemic interval, and ischemia x post-ischemic interval (F1, 16 = 9.07, P =
0.0083; F3, 16 = 3.73, P = 0.0332; F3, 16 = 4.55, P = 0.0173, respectively) on relative
torsinA radioactivity in the SNpc. In addition, individual contrasts between the ischemia
and sham groups were significant (P < 0.05) at the 24 hr post-ischemic interval.
2.3.2 TorsinA Was Up-regulated in Hippocampal Astrocytes and Interneurons
Changes in torsinA immunocytochemistry were consistent with the hybridization
results, and permitted signal localization to specific cell types. The initial increase in
torsinA-IR at 24 hr occurred in the major hippocampal neuron populations that exhibited
endogenous expression, whereas later diffuse increases overlapped the distributions of
glial activation and synaptophysin up-regulation that took place in regions of CA1 neuron
loss (Figure 2-5).
Double labeling (Figure 2-6) identified torsinA co-localization in GFAP-positive
astrocytes but not OX-42-labeled microglia. Additional cells strongly-IR for torsinA
included parvalbumin and somatostatin-IR interneurons. As seen in Figure 2-7,
hippocampal somatostatin and parvalbumin interneurons were torsinA-IR in postischemic and sham tissues. However, after ischemia, the relative intensity of torsinA-IR
was higher in these cell types than in adjacent neurons. Many of the parvalbumin-IR
interneurons were scattered among pyramidal cells in the hippocampal pyramidal cell
layer and granule cells in the dentate gyrus whereas others were localized to the dentate
hilus and near the edge of the SO. Most of the somatostatin-IR interneurons were found
in the dentate subgranular proliferative zone, dentate hilus, SO and the boundary region
between the SR and SLM.
As seen in Figure 2-8, torsinA-IR was increased in neurons in the subgranular
proliferative zone and hilus of the dentate gyrus, and pyramidal cells of the CA2 and CA1
regions at 24 hr post-ischemia. At 7 d post-ischemia, torsinA-IR was mildly decreased in
CA1 pyramidal cells, and increased in neurons in the subgranular proliferative zone and
hilus of the dentate gyrus, CA3/CA2 pyramidal cells, and the cells in the SR. In the 14 d
post-ischemic hippocampus, robust torsinA-IR was apparent in cells scattered within the
SR and hilus of the dentate gyrus, and moderately-IR cells were sparsely distributed
within the SO.
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Figure 2-4. Quantitative in situ hybridization analysis of torsinA transcript levels in
SNpc.
TorsinA hybridization signal was expressed relative to the mean value for sham sections
hybridized in each experimental run. A small but significant increase in torsinA
transcript was observed at 24 hr after ischemia. Results are expressed as the mean ± SEM
(*, P < 0.05 for the difference between ischemic and sham groups at each post-ischemic
interval).
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Figure 2-5. Distribution of torsinA immunoreactivity and comparison with other markers.
Torsin A-IR was moderately increased in the major hippocampal neuron populations at the 24 hr post-ischemic interval, and
overlapped the distributions of astrocyte (GFAP) and microglial (OX-42) activation and synaptophysin upregulation at later
intervals. Confocal gray scale images of fluorescent immunocytochemistry are shown for torsinA (antibody TA1), GFAP, and
OX-42, and inverted gray-scale images of peroxidase detection are shown for synaptophysin. Scale bar, 500 μm
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Figure 2-6. Cellular localization of torsinA immunoreactivity in glia.
High-magnification confocal images of double-label fluorescent immunocytochemistry
for simultaneous detection of torsinA (green, right column gray scale) and cell markers
GFAP, OX-42 (red, middle column gray scale) in post-ischemic (7 d) hippocampus.
TorsinA co-localizes with GFAP-positive astrocytes but not OX-42-labeled microglia.
Double-labeled cells appear yellow in the merged images. Scale bar, 50 µm.

33

Figure 2-7. Cellular localization of torsinA immunoreactivity in interneurons.
High-magnification confocal images of double-label fluorescent immunocytochemistry
for simultaneous detection of torsinA (green, right column gray scale) and cell markers
parvalbumin and somatostatin (red, middle column gray scale) in sham and post-ischemic
(7 d) hippocampus. TorsinA-IR is prominent in neurons that express parvalbumin and
somatostatin (arrows). Double-labeled cells appear yellow in the merged images. Scale
bar=50 µm.
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Figure 2-8. Immunoperoxidase detection of torsinA in post-ischemic hippocampus.
Using the TA1 polyclonal antibody, increased torsinA-IR was detected in the cells in the
subgranular proliferative zone (arrow) and hilus of the dentate gyrus, and in the
pyramidal cells in CA3 and CA2 region at all time points after ischemia, and in cells
scattered within the SR and SO of CA1 at 14 d after ischemia. M, molecular layer; G,
granule cell layer; and H, hilus of the dentate gyrus. Scale bar, 200 µm.
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2.3.3

TorsinA Transcript and Protein Were Up-regulated in Bilateral DRG after
Unilateral Sciatic Nerve Transection

TorsinA mRNA expression was increased after sciatic nerve transection (Figure
2-9), as assessed by QRT-PCR. The amplification efficiencies for torsinA and GAPDH
were 0.95 and 1.01, respectively, and the slope of ΔCT versus log10 ng total RNA was
-0.043. The CT values associated with torsinA and GAPDH amplification showed strong
linear relationships with log10 ng total RNA (torsinA: R2 = 0.94; GAPDH: R2 = 0.99).
The overall effect of sciatic nerve transection was robust in contralateral DRG (F5, 12 =
8.31, P = 0.0015), but did not reach statistical significance in ipsilateral DRG (F5, 11 =
2.47, P = 0.098). Post-hoc contrasts showed that torsinA expression differed between the
control and surgical groups in ipsilateral and contralateral DRG at 24 hr and 3 d (P <
0.05, for all), with a significant increase that persisted in the contralateral DRG at 7 d (P
< 0.05).
In control DRG, torsinA-IR was detected in satellite cells, the somas of ganglion
cells, and axons (Figure 2-10). After sciatic nerve transection, torsinA-IR increased in
ganglion and satellite cells ipsilateral to the lesion, but only in satellite cells
contralaterally. In ipsilateral ganglion cells, torsinA-IR was most prominent at 3 and 7 d
after sciatic nerve transection. GFAP-IR co-labeled torsinA-positive satellite cells
(Figure 2-11).
2.3.4

TorsinA and Vimentin Co-localize in Neuronal and Glial Elements in the
CNS and PNS

Given the apparent up-regulation of GFAP after CNS and PNS insults and
prominent expression of torsinA in GFAP-IR reactive astrocytes and satellite cells, we
elected to localize a closely related intermediate filament protein, vimentin, in
hippocampus and DRG (Figure 2-12). Vimentin-IR interneurons and reactive astrocytes
were readily apparent in post-ischemic hippocampus. In interneurons, vimentin-IR was
diffuse and co-localized with torsinA-IR. Although many reactive astrocytes expressed
vimentin and torsinA, co-localization of vimentin- and torsinA-IR was weak in these
cells. After sciatic nerve transection, vimentin-IR was readily visualized in satellite cells
of the ipsilateral and contralateral DRG.
2.4

DISCUSSION

In normal brain, expression of torsinA is high in neurons and low in glia, and its
developmental regulation indicates that torsinA might play a role in postnatal
maturational events in the CNS (Xiao et al., 2004). The present results indicate an altered
pattern of torsinA expression, which notably involved astroglial cell types, after
challenges to the central and peripheral nervous systems. The similar quantitative and
temporal features of torsinA up-regulation after sciatic nerve transection and 4-VO
suggest the presence of common transcriptional control mechanisms, as well as a
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Figure 2-9. Temporal profiles of torsinA mRNA expression in DRG after unilateral
sciatic nerve transection.
TorsinA mRNA expression levels in ipsilateral and contralateral DRGs were calculated
in reference to the mean CT value for all DRG from control rats (C). Prominent bilateral
increases in torsinA transcript were observed bilaterally at 1 and 3 days. Symbols indicate
the mean ± SEM (*, P < 0.05 for the difference between lesioned and control animals).

39

Figure 2-10. Immunocytochemical localization of torsinA expression in DRG after
unilateral sciatic nerve transection.
TorsinA-IR increases were detected ipsilaterally in both ganglion cells (G) and satellite
cells (arrow), but only in satellite cells contralaterally. C, non-surgical control. Scale
bar, 100 µm.
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Figure 2-11. Co-localization of torsinA and GFAP in satellite cells.
Confocal images of fluorescent immunocytochemistry illustrate co-localization in
satellite cells (arrow) of ipsilateral DRG 14 d after sciatic nerve transaction. Colocalization appears yellow in the merged images. G, ganglion cell. Scale bar, 50 µm.
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Figure 2-12. Co-localization of torsinA and vimentin after ischemia and sciatic
nerve transection.
Confocal images of fluorescent immunocytochemistry illustrate co-localization in a
subset of CA3 interneurons and CA1 astrocytes in 7 d post-ischemic hippocampus.
Vimentin also co-localizes with the component of torsinA expression in satellite cells
(arrow) of ipsilateral DRG 14 d after sciatic nerve transection. Co-localization appears
yellow in the merged images. G, ganglion cell. Scale bars, 50 µm (top three panels) and
25 µm (other panels).
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common role for this protein in the reparative and/or adaptive responses to such
perturbations.
2.4.1

Post-ischemic TorsinA Expression in the CNS

Brief durations of global ischemia such as those used in these studies resulted in a
selective loss of hippocampal CA1 pyramidal cells and interneurons of dentate hilus
(Pulsinelli et al., 1982a; Nishino and Nowak, 2004; Ueda and Nowak, 2005). However,
4-VO produces severe reductions in blood flow throughout forebrain structures, as wellas
appreciable perfusion deficits in cerebellum and brainstem (Pulsinelli et al., 1982b). The
rapid, generalized increase in torsinA transcript levels throughout the brain (Figure 2-1)
that maintain the distribution in major neuron populations seen in control brain (Figure
2-2) appears to reflect a relatively homogeneous response to this initial ischemic insult.
This parallels, in many respects, the acute post-ischemic induction of many ischemiaresponsive genes, including many heat shock proteins (Nowak, 1991; Kawagoe et al.,
1992; Xue et al., 1998; Nowak and Kiessling, 1999; Yagita et al., 2001; Tanaka et al.,
2002). Studies in other in vivo and in vitro models also suggest a role for torsinA in
response to oxidative stress (Hewett et al., 2003; Kuner et al., 2004; Cao et al., 2005).
In contrast, the delayed component of torsinA increase includes prominent
expression in reactive astrocytes in regions of hippocampus (e.g., CA1) known to
undergo neuron loss and synaptic reorganization after ischemia (Arabadzisz and Freund,
1999; Briones et al., 2004). In agreement with previous work, astrocytic and microglial
markers showed the most prominent post-ischemic response in the CA1 region (SchmidtKastner et al., 1990; Morioka et al., 1991; Gottlieb and Matute, 1999). Although not
specifically evaluated in this study, the persistent modest increase in torsinA expression
noted in cerebellum (Figure 2-1) might be a correlate of glial activation in response to
Purkinje cell vulnerability that also has been described after global ischemia (Diemer and
Siemkovicz, 1981).
Astrocytes are believed to carry out protective functions such as maintenance of
ionic homeostasis, prevention of excitotoxicity (via glutamate uptake), scavenging free
radicals, provision of nutrients and growth factors, and support of synaptogenesis and
neurogenesis (Panickar and Norenberg, 2005). Astrocytes are associated with the
synapses, enwrap many pre- and post-synaptic terminals, and facilitate synaptic
formation and synaptic neurotransmitter release (Araque et al., 1999; Grosche et al.,
1999; Ventura and Harris, 1999; Riquelme et al., 2002; Liu et al., 2004; Sobkowicz et al.,
2006). The up-regulation of torsinA in reactive astrocytes might facilitate one or more
protective functions of astrocytes such as glutamate uptake via movement of the
polytopic glutamate transporter to the cell surface. Alternatively, torsinA might
contribute to the morphological and topological changes that reactive astrocytes must
undergo in order to facilitate synaptogenesis and network reorganization (Lepekhin et al.,
2001; Witcher et al., 2007).
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These results also demonstrate an up-regulation of torsinA expression in surviving
somatostatin- and parvalbumin-IR interneurons (Figure 2-7), which likely contribute to
the partial maintenance of torsinA transcript levels in the CA1 stratum pyramidale at late
post-ischemic intervals despite the death of most pyramidal neurons (Figure 2-3). It is
well established that parvalbumin-IR interneurons in the hippocampus are resistant to
ischemic stress (Nitsch et al., 1989; Ferrer et al., 1995). Similarly, somatostatin-IR
interneurons in the CA1 region are also relatively resistant to ischemia (Bering and
Johansen, 1993; Bering et al., 1997). Surviving interneurons in the CA1 region undergo
significant morphological changes, and may serve as substitute targets for Schaffer
collateral and other excitatory synaptic input after hippocampal ischemia (Arabadzisz and
Freund, 1999). Accordingly, it is rational to postulate that torsinA might participate in
structural changes and/or transport of cell surface receptors in these hippocampal
interneurons.
Transient global ischemia is followed by neurogenesis in the subgranular
proliferative zone (Sharp et al., 2002; Kokaia and Lindvall, 2003), and there is some
evidence to suggest a parallel response in the posterior periventricular zone adjacent to
the hippocampus (Nakatomi et al., 2002). Neuroblasts that originate from the
subgranular proliferative zone give rise to neurons within the granule cell layer and
GFAP-IR astrocytes in the dentate hilus. Although BrdU labeling was not examined in
this study, the numerous cells robustly-IR for torsinA in the subgranular proliferative
zone (Figure 2-8) might be such neuroblasts. Developmental profiles of torsinA
transcript and protein expression are also consistent with a role for torsinA during
neurogenesis in brain (Xiao et al., 2004).
2.4.2 TorsinA in the Injured PNS
TorsinA is constitutively expressed in the PNS, where it is present in neuronal and
glia elements (ganglion and satellite cells, respectively) in the DRG. After unilateral
sciatic nerve transection, torsinA transcript increased bilaterally (Figure 2-9). TorsinA
immmunoreactivity was detected in both cell types in the DRG ipsilateral to the lesion,
but was more prominently increased in satellite cells contralaterally (Figure 2-10).
Bilateral effects of sciatic nerve transection are consistent with work from other
laboratories. Ryoke and colleagues (2000) reported that a conditioning lesion (i.e., left
sciatic nerve transection) enhanced expression of IL-1β and TGF-β in the contralateral
DRG and promoted nerve regeneration. Similarly, increased expression of four cytokines
(IL-1β, TGF-β1, TNF-α, and IL-10) was apparent in contralateral DRG for up to 35 days
after sciatic nerve transection (Ruohonen et al., 2002). Up-regulation of torsinA in
ipsilateral ganglion cells is consistent with its potential role in the response to cellular
stress as noted above in the context of cerebral ischemia. However, the mechanism for
up-regulation of torsinA in contralateral satellite cells is less obvious. Satellite cells
appear to play important roles in the physiology of their contiguous ganglion cells
(Dublin and Hanani, 2007; Kuo et al., 2007). Satellite cells exhibit increased gapjunction coupling in response to the ipsilateral application of noxious stimuli (Dublin and
Hanani, 2007). Up-regulation of p75 in satellite cells appears to be responsible for
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sympathetic sprouting in the DRG after peripheral nerve lesions (Hu and McLachlan,
2000). Because unilateral sciatic nerve transection is associated with compensatory
changes in gait and appendicular loads, up-regulation of torsinA in contralateral satellite
cells could be related to the increased signaling demands on the adjacent ganglion cells.
Alternatively, up-regulation of torsinA in satellite cells could be part of a generalized
response to the surgical intervention, possibly due to plasma TGF-β. Interestingly, work
in Drosophila suggested that TGF-β signaling might be defective in DYT1 dystonia (Koh
et al., 2004). Over-expression of Smad2, a downstream effector of TGF- β, suppressed
ultrastructural defects at the neuromuscular junction in ΔGAG human torsinA flies.
2.4.3

TorsinA Function

TorsinA protein is structurally related to the ClpB/Hsp100 family of proteins,
which have been shown to have unfoldase activities (Hong and Vierling, 2000;
Weibezahn et al., 2004; Ung et al., 2007). According to the evidence that torsinA was
found localized to protein aggregations such as Lewy bodies in Parkinson's disease brain
and inclusion bodies in trinucleotide repeat diseases, and its overexpression facilitated
clearance of the aggregates (Shashidharan et al., 2000b; Sharma et al., 2001; McLean et
al., 2002; Walker et al., 2003; Caldwell et al., 2003) and overexpression of torsinA
facilitated clearance of another dystonia-related protein, SGCE, by the ubiquitin
proteosome system (Esapa et al., 2007), torsinA is hypothesized to play a similar role as
an unfoldase in mammalian systems (McLean et al., 2002; Kuner et al., 2003).
Several largely-independent lines of evidence indicate that torsinA contributes to
the brain development and might regulate neurite extension and synaptic functioning.
TorsinA was strikingly expressed in prenatal and early postnatal period, with the most
intense expression in cerebellar Purkinje cells, striatal cholinergic interneurons, and SNpc
dopaminergic neurons at postnatal day 14 (Xiao et al., 2004), a period of intense cellular
migration, neurite extension, and synaptogenesis. TorsinA knock-out and homozygous
ΔGAG knock-in mice die shortly after birth (Goodchild et al., 2005). TorsinA was found
localized to the neurites and synapses (Augood et al., 2003; Konakova et al. 2001;
Konakova and Pulst, 2001; Kuner et al., 2003; Kamm et al., 2004). Overexpression of
mutant torsinA inhibited neurite extension; however, attenuation of wild-type torsinA
facilitated neurite extension (Ferrari-Toninelli et al., 2004; Hewett et al., 2006). In
addition, torsinA was found to interact with snapin, a SNARE-associated protein, and to
control synaptic-vesicle recycling (Ilardi et al., 1999; Granata et al., 2008). TorsinA was
also interacted with kinesin light chain, a motor protein to transport cargos from cell body
to synapses along microtubules (Kamm et al., 2004).
Other evidence suggests that torsinA might maintain the structure of the nuclear
envelope and endoplasmic reticulum by interacting with cytoskeletal proteins. TorsinA
knock-out, homozygous ΔGAG knock-in, and ΔGAG transgenic mice showed
morphological abnormalities of the nuclear envelope (Goodchild et al., 2005; Grundmann
et al., 2007). TorsinA co-immunoprecipitates with a multi-molecular complex that
includes cytoskeleton proteins (vimentin, tubulin, and actin), a motor protein (KLC1),
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nuclear envelope proteins (LAP1 and nesprin), an endoplasmic reticulum protein
(LULL1), and a linker protein (plectin) (Goodchild and Dauer, 2005; Hewett et al., 2006;
Nery et al., 2007). The linker protein plectin links the nuclear envelope to the
cytoskeleton by an interaction with nesprin, an outer nuclear membrane protein
(Wilhelmsen et al., 2005). In vitro studies have shown that mutant torsinA interferes
with cytoskeletal events that involve vimentin (Hewett et al., 2006). Vimentin, a
member of the intermediate filament family of proteins, is expressed in the developing
brain (Sancho-Tello et al., 1995; Hutchins and Casagrande, 1989), and is also induced in
reactive glia (Kindy et al., 1992; Braun et al., 1998). Vimentin plays an important role in
cellular morphology and organelle positioning (Goldman et al., 1996).
2.5

CONCLUSIONS

Neurodevelopmental abnormalities might be central to the pathobiology of DYT1
dystonia, given that generalized dystonia rarely develops during adulthood in ΔGAGmutation carriers (Bressman et al., 2000; Carbon et al., 2008b). On the other hand, the
reduced penetrance of the ΔGAG TOR1A mutation suggests that a perturbation (e.g.,
trauma, hypoxia, severe febrile illness, intense sensorimotor training) to the CNS or PNS
might be required for the appearance of a dystonic phenotype. Hypoxic-ischemic insults
are believed to be pathogenic in cases of dystonic cerebral palsy (Kyllerman, 1982;
Treves and Korcyzyn, 1986; Cerovac et al., 2007), an example of secondary dystonia,
and it is conceivable that perinatal factors such as hypoxia-ischemia might increase
expressivity of dystonia in carriers of the DYT1 mutation. Its well-demarcated gross
anatomy and precise intrinsic connections make the post-ischemic rat hippocampus an
ideal model system in which to study the reactive synaptogenesis, astrocytosis, and
neurogenesis that follows the loss of CNS neurons, and sciatic nerve transection offers
comparable advantages in the PNS. The induction of torsinA in glia suggests a novel
avenue through which to explore the cellular and systems pathopathophysiology of
DYT1 dystonia.
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CHAPTER 3. BEHAVIOR, MORPHOLOGICAL, NEUROCHEMICAL, AND
METABOLIC FEATURES OF DYT1 ΔGAG TRANSGENIC MICE *
3.1

INTRODUCTION

Although the cellular function of mutant torsinA has been explored with a variety
of in vivo approaches, the data generated in these studies do not provide a clear link
between the molecular biology of torsinA and the development of dystonia. However,
post-mortem studies have provided evidence that functional abnormalities and/or
ultrastructural abnormalities rather than neurodegeneration underlie DYT1 dystonia and
pointed to the nigrostriatal pathway as a potential site of neuropathological significance
in human DYT1 dystonia. Rostasy and colleagues (2003) failed to disclose any
consistent evidence of neuronal loss, inflammation, or neurodegeneration in DTY1
dystonia, but they did detect an increased nigral cell density along with somatic
enlargement of nigral dopaminergic neurons in the brains of DYT1 dystonia patients. A
significant increase in DA turnover and a decline in dopamine D1 and D2 receptor
binding have also been established in DYT1 dystonic striatum (Augood et al., 2002). In
addition, functional neuroimaging studies have identified an increased metabolic activity
in the putamen, cerebellum, and SMA in carriers of the DYT1 mutation (Eidelberg, 1998;
Carbon et al., 2004a). Together with evidence of high-level expression of torsinA
transcript and protein within dopaminergic neurons of the SNpc during brain
development (Konakova et al., 2001; Konakova and Pulst, 2001; Augood et al., 2003;
Oberlin et al., 2004; Xiao et al., 2004; Vasudevan et al., 2006), these findings suggest that
torsinA might be important for nigrostriatal development and function, whereby a mutant
and non-functional protein could lead to aberrant nigrostriatal function and the
subsequent development of dystonia.
Unfortunately, the above-noted dopaminergic aberrations in human DYT1
dystonia have not been replicated in independent studies. Furthermore, the available data
are limited by the number of brains examined in each study (Augood et al., 2002; Rostasy
et al., 2003; Asanuma et al., 2005). Genetically modified animal models are useful tools
to investigate the contributing effects of mutant torsinA to the onset of DYT1 dystonia,
investigate and confirm findings in human patients, and open the door for future studies.
Current thinking related to AAA+ proteins suggests that a single mutant torsinA
molecule could disrupt assembly of functional torsinA homohexamers. Accordingly,
intense transgenic expression of mutant torsinA should interrupt the function of
endogenous torsinA by interfering with formation of intact homohexamer. On this
background, Sharma and colleagues (2005) developed the hMT1, hMT2, and hWT lines
of mice. In these transgenic mice, either human wild-type or mutant torsinA are driven
by the human cytomegalovirus (CMV) immediate early promoter. Because there is no
*
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tag added to the human torsinA cDNA in the expression vector, the expression of the
exogenous gene cannot be evaluated in the transgenic mice. However, previous studies
have reported that CMV promoters drive widespread expression of exogenous genes in
the neurons and astrocytes, (Fritschy et al., 1996; van den Pol and Ghosh, 1998).
Furthermore, under the CMV promoter the cellular pattern of expression involves entire
neuronal arbors, transcripts and their protein products are not restricted to aberrant
cellular compartments (van den Pol and Ghosh, 1998). Therefore, the models developed
by Sharma colleagues are suitable for the study of DYT1 dystonia. In previous work,
transgenic mice that express mutant torsinA show reduced ability to learn motor skills in
an accelerating rotarod paradigm at six months of age, as well as abnormal dopaminergic
D2 receptor responses in striatal cholinergic interneurons (Pisani et al., 2006).
Furthermore, amphetamine-induced DA release is attenuated in the hMT1 mice
(Balcioglu et al., 2007). Of note, the hMT1 and hMT2 mice do not exhibit dystonia.
Moreover, no other murine model of DYT1 dystonia actually manifests dystonia. These
results are not entirely unexpected, because the penetrance of the human DYT1 ΔGAG
mutation is less than 40%. In conclusion, hMT mice can be viewed as models of the
DYT1 carrier state.
In the work described herein, we rigorously characterized the behavioral,
morphological, neurochemical, and brain metabolical features of the hMT1 transgenic
model of the DYT1 carrier state. As shown below, the hMT1 line exhibits robust
transgene expression. Specifically, a comprehensive battery of behavorial tests was used
to identify motor abnormalities in hMT1 mice. Electron and confocal microscopy were
employed to evaluate previous reports of neuronal nuclear bleb formation and ubiquitinpositive cytoplasmic inclusions, respectively, in human DYT1 dystonia and other murine
models of DYT1 dystonia (McNaught et al., 2004; Dang et al., 2005; Goodchild et al.,
2005; Shashidharan et al., 2005; Grundmann et al., 2007). High-performance liquid
chromatography with electrochemical detection (HPLC-EC) was carried out to
comprehensively quantify monoaminergic neurotransmitters and their metabolites in
multiple neural structures. Finally, 2-deoxy-D-glucose (2-DG) utilization, as well as
cytochrome oxidase (CO) histochemistry, was performed to evaluate short- and longterm brain metabolic demands.
3.2

METHODS

3.2.1

DYT1 Transgenic Mouse Model and Genotyping

Breeding colonies of hWT, hMT1, and hMT2 mice were established at the
University of Tennessee Health Science Center by matings with wild-type (WT)
C57BL/6J mice. All mice used in experiments were C57BL/6J backcrossed at least 8X.
Tail DNA from the breeders and their offspring were isolated with the AquaPure
Genomic DNA Tissue Kit (Bio-Rad Laboratories, Hercules, CA, USA) for genotyping.
The primer pair used for genotyping analysis is detailed in Table 3-1. The primers
amplified a 560-bp segment (35 cycles; annealing temperature - 60°C) within the human
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Table 3-1. Probe and primers used for QRT-PCR, and primers used for generation
of Northern blot probes.
Name
GF1
GR1
TOR1AF
TOR1AR
TOR1SF
TOR1SR
TOR2AF
TOR2AR
TOR2SF
TOR2SR
Actb1AF
Actb1AR
Actb1SF
Actb1SR
QF1-h
QR1-h
QP1-h
QF1-m
QR1-m
QP1-m

Sequence (5’→3’)

Locus

NM_000113
479 – 500 nt
NM_000113
cgttttgcagcctttatctga
1040 – 1020 nt
NM_000113
gcgtctctactgcctcttcg
197– 216 nt
gataatacgactcactatagggt NM_000113
ggacatagtcactgttcag
466– 447 nt
gataatacgactcactataggg NM_000113
gcgtctctactgcctcttcg
197– 216 nt
NM_000113
tggacatagtcactgttcag
466– 447 nt
NM_000113
acaagaacagtggcttctggca
817 – 838 nt
gataatacgactcactataggg NM_000113
ggtgaacaccgttttgcagc
1049 – 1030 nt
gataatacgactcactataggg NM_000113
acaagaacagtggcttctggca 817 – 838 nt
NM_000113
ggtgaacaccgttttgcagc
1049 – 1030 nt
NM_144884
agcaagagaggtatcctga
257 – 275 nt
gataatacgactcactataggg NM_144884
acagcacagcctggatggcta 500–480 nt
gataatacgactcactataggg NM_144884
agcaagagaggtatcctga
257 – 275 nt
NM_144884
acagcacagcctggatggcta
500–480 nt
NM_000113
gcgtctctactgcctcttcg
197 – 216 nt
NM_000113
ggttgtcgtccagatccttc
282 – 263 nt
NM_000113
gggcagaag
229 – 236 nt
NM_144884
ccgtgtcggtcttcaataaca
769 – 789 nt
aataatctatgaggttccggtca NM_144884
a
843 – 820 nt
NM_144884
cagcagcc
809 – 816 nt
cacattgcactttccacatgct
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Usage

Product (bp)

Genotyping
Genotyping
antisense probe
1
antisense probe
1

560 (with
GF1)
270 (with
1AF)

sense probe 1
sense probe 1
antisense probe
2
antisense probe
2

270 (with
1AF)
233 (with
2AF)

sense probe 2
sense probe 2
β-actin
antisense probe
β-actin
antisense probe
β-actin sense
probe
β-actin sense
probe

233 (with
2SF)
244 (with
Actb1AF)
244 (with
Actb1SF)

RT-PCR
RT-PCR

86 (with
QF1-h)

RT-PCR
RT-PCR
RT-PCR
RT-PCR

75 (with
QF1-m)

torsinA coding sequence that was identified via 1% agarose gel electrophoresis (Figure
3-1A). The genotype of the breeders was confirmed by restriction digestion with BseRI
(New England BioLabs, Ipswich, MA, USA). The human WT torsinA PCR product was
digested with BseRI into four fragments (279 bp, 238 bp, 24 bp, and 22 bp). The human
mutant torsinA PCR product was digested with BseRI into three fragments (279 bp, 259
bp, and 22 bp). Fragment profiles were identified with 2% agarose gel electrophoresis
(Figure 3-1B).
3.2.2 Northern Blot Hybridization
Whole-brain RNA from WT (n = 4), hWT (n = 4), hMT1 (n = 3), and hMT2 (n =
4) mice were extracted with TRI reagent® (Ambion, Austin, TX, USA) and DNA was
removed with DNA-freeTM. Total RNA quality was examined with agarose gel
electrophoresis and a NanoDrop® ND-1000 spectrophotometer. Pooled human whole
brain RNA was obtained from Ambion (Human Brain Reference RNA, n = 23 brains).
The MicroPoly(A)Purist (Ambion) kit was used to extract mRNA from total RNA. The
mRNA was electrophoretically resolved on denaturing gels and transferred to positively
charged nylon membranes. Radiolabeled (32P-UTP) cRNA probes were generated by in
vitro transcription with T7 RNA polymerase. Primer pair sequences to make the
radioactive probes are described in Table 3-1. After ultraviolet crosslinking, blots were
prehybridized and hybridized overnight with TOR1A and Actb (β-actin) cRNA probes.
The TOR1A probe was generated from human cDNA template, whereas the Actb probe
was generated from mouse cDNA template. After washing, blots were exposed to Kodak
Biomax MR radiographic film prior to development.
3.2.3 QRT-PCR
Reverse transcription was performed with Ambion's RETROscriptTM kit with 500
ng total RNA as template. The reaction mixture was incubated at 44 ºC for 1 hr and at 92
ºC for 10 min. QRT-PCR was performed with the Roche LightCycler 480 with genespecific primers and Universal Taqman® probes (Table 3-1; Roche Applied Science,
Indianapolis, IN, USA) for the target genes (human torsinA and mouse torsinA) and
endogenous control (Cyclophilin D). Relative levels of human torsinA transcript in
mouse brain were calculated relative to Human Brain Reference RNA and total RNA
from normal human striatum (Stratagene, La Jolla, CA, USA; n = 1 brain), whereas levels
of mouse torsinA mRNA (hWT [n = 4], hMT1 [n = 3], and hMT2 [n = 4]) and striatal
(hWT [n = 6], hMT1 [n = 8], and hMT2 [n = 4]) were calculated relative to WT
littermates (whole brain [n = 4] and striatum [n = 6]).
3.2.4 Behavioral Assessment
Adult (3–4 month) male hWT (n = 24) and hMT1 (n = 35) mice, along with WT
(n = 20) age- and gender-matched littermate controls, were used for quantitative analyses
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Figure 3-1. Genotyping and Northern blot analysis of hWT, hMT1, and hMT2
transgenic mice.
Gel images of PCR products before (A) and after (B) digestion are shown. Products from
hMT1 or hMT2 mice appear in lanes 1, 2, and 4, whereas products from hWT mice
appear in lanes 3, 5, and 6. (C) Northern blot analysis of equal amount of poly-A RNA
obtained from brain tissues of human, WT, hWT, hMT1, and hMT2 mice. Human
torsinA probes recognized a 1.5 kb band in transgenic mice, and a 2.5 kb band in human
brain. Mouse β-actin (loading control) appeared as a 2.0 kb band below each lane.
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of motor functions (Jiao et al., 2005). In addition, hMT1, hMT2, and hWT mice,
including animals over one year of age, were routinely observed for evidence of dystonia
during open-field behavior.
3.2.4.1 Rotarod Performance
Mice were acclimated to a Rotamex-5 rotarod (Columbus Instruments, Columbus,
OH, USA) that rotated at 5 rpm for 5 min one day prior to data acquisition. Two motor
assessments were performed. The first assessment began with a 30 s acclimation period
at 4 rpm, followed by an acceleration of 4 rpm every 30 s to a maximum of 5 min at 40
rpm. Mice were given three trials at the same time each day for 5 consecutive days. The
second assessment began with an initial speed of 4 rpm, which gradually accelerated at a
rate of 1 rpm every 5 s to an incremented target speed for 5 consecutive days (5, 10, 20,
30, and 40 rpm, respectively). Transgenic and WT littermate mice were randomly
selected for one of these two trials. All tests were performed in technical triplicate, and
median values were used for statistical comparison.
3.2.4.2 Footprint Analysis
Mouse forepaws (green) and hindpaws (red) were dipped in nontoxic water-based
paints. Mice were allowed to walk down an enclosed runway lined with white paper.
Three trials were performed on three separate days within one week. Two to four steps
from the middle portion of each run were measured for (1) stride length, (2) hind-base
width (the distance between the right and left hindlimb strides), and (3) front-base width
(the distance between the right and left forelimb strides). At least seven steps were
measured for each mouse. Mean values were used for statistical analysis.
3.2.4.3 Tail Suspension
This test involved the response of each mouse to 1 min of vertical suspension
from the tail. Neurological dysfunction is exhibited as hindlimb and/or forelimb clasping
during this maneuver.
3.2.4.4 Vertical Rope Climb
Mice were acclimated to a vertical, 40-cm long, 10-mm thick nylon rope prior to
testing. The bottom of the rope was suspended 15 cm above a padded base, and the top
entered into a darkened escape box. Three trials with a 5-min intertrial interval were
completed for each mouse. Median times were used for statistical analysis.
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3.2.4.5 Raised-beam Task
Mice were acclimated to an 80-cm long, 20-mm wide beam elevated 50 cm above
a padded base. A 60W lamp at the start served as an aversive stimulus, whereas the
opposite end of the beam entered a darkened escape box. Transversal time and number of
slips were measured as mice traversed the beam. After initial testing with a 20-mm
diameter square beam, mice were given follow-up tests using supplementary round (8mm and 12-mm diameter) and square (12-mm diameter) beams. All testing was
performed in triplicate, and median values were used for subsequent statistical analyses.
3.2.5

Confocal Microscopy

Adult (3–4 month) male WT (n = 3), hWT (n = 3), and hMT1 (n = 3) mice were
overdosed with pentobarbital (100 mg/kg, IP) prior to transcardiac perfusion with
heparinized saline and 4% paraformaldehyde/0.1 M PB. Brains were dissected, postfixed in 4% paraformaldehyde for another 2 hrs, and incubated in a cryoprotectant
solution (30% sucrose/0.1 M PB, pH 7.4) for at least 48 hrs. Brains were sectioned at 20
μm on a cryostat, collected onto SuperFrost®-Plus glass slides, circled with a PAP pen,
and allowed to dry on a slide warmer for 10 min. Sections were blocked in 2% nonfat
dry milk and 0.3% Triton X-100 in 0.02 M PBS, and incubated overnight with mouse
monoclonal anti-torsinA antibody D-M2A8 (1:300 diluted in PBS with 3% normal
donkey serum and 0.1% Triton X-100) and rabbit polyclonal anti-ubiquitin antibody
(1:1000; Dakocytomation, Carpinteria, CA, USA). Sections were incubated for 4 hr with
biotinylated horse anti-mouse (1:500) and RRX- tagged donkey anti-rabbit secondary
antibodies (1:250) diluted in PBS with 2% normal donkey serum and 0.1% Triton X-100.
After rinsing with PBS, sections were incubated for 1 hr with Cy2-tagged streptavidin
(1:500) diluted in PBS with 0.1% Triton X-100. Sections were rinsed, air-dried,
dehydrated, cleared, and coverslipped with DPX mounting compound. Sections were
visualized with epifluorescence (Leica DM6000) and confocal laser-scanning
microscopy.
3.2.6

Electron Microscopy

Adult (3–4 month) male WT (n = 3), hWT (n = 3), and hMT1 (n = 3) mice were
overdosed with pentobarbital (100 mg/kg, IP) prior to transcardiac perfusion with
heparinized saline and 4% paraformaldehyde/2.5% glutaraldehyde/15% picric acid in 0.1
M PB. The brains and cervical spinal cords were dissected from surrounding tissue.
Regions of interest (striatum, pons, cerebellar cortex, and spinal cord) were cut into 3 x 3
x 3 mm blocks that were post-fixed overnight. Tissue blocks were post-fixed in 1%
osmium tetroxide (Electron Microscopy Sciences, Hatfield, PA, USA) in PBS for 4 hrs,
and were rinsed briefly in deionized water. After ascending dehydration in 30%, 50%,
70%, 85%, 95%, and 3 X 100% ethanol (each for 30 min), tissue blocks were infiltrated
with 50% Spurr (Electron Microscopy Sciences) in 100% ethanol overnight at room
temperature, and 100% Spurr over 8 hrs. Blocks were cured at 70 °C for 2 days. One-
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micrometer sections were cut on a Reichert Ultracut E microtome (Reichert Instruments,
Depew, NY, USA), and were stained with toluidine blue. Areas of interest were selected,
sectioned at 75 nm, mounted onto 150-mesh grids, and post-stained with 4% uranyl
acetate in methanol and Venable lead citrate. Sections were visualized, and were
photographed with a JEOL 2000EX transmission electron microscope (JOEL USA Inc.,
Peabody, MA, USA) at 60 kV with 30,000X magnification.
3.2.7 HPLC-EC Analysis of Monoamines and Their Metabolites
All standards, including 5-HIAA, 5-HT hydrochloride, DA hydrochloride,
DOPAC, epinephrine hydrochloride (EPI), HVA, and NE hydrochloride, were of
analytical grade, and were purchased from Sigma-Aldrich. Sodium octylsulphonate
(SOS) and monobasic anhydrous sodium dihydrogen phosphate used in mobile-phase
preparation were purchased from Fluka Chemie (Buchs, Switzerland). HPLC-grade
water and acetonitrile were obtained from Fisher Scientific.
Tissues from adult (3-4 month) male hWT (n = 10) and hMT1 (n = 11) mice,
along with WT (n = 10) age- and gender-matched littermate controls were analyzed with
HPLC-EC to quantify cerebral cortical, striatal, and cerebellar levels of DA, NE, EPI, 5HT, DOPAC, HVA, and 5-HIAA.
Fresh samples of striatum, cerebellar cortex, and cerebral cortex were weighed
and homogenized in 100 μl of an ice-cold solution of 0.1 M perchloric acid, 0.1 mM
sodium metabisulfite, and 0.1 mM EDTA per 10 mg wet weight. Homogenates were
centrifuged at 20,000 g for 25 min at 4 °C. Supernatants were filtered through 0.22 µm
pore size polyvinylidene fluoride syringe-driven membrane filters (Millipore Corp.,
Bedford, MA, USA), and the filtrate was immediately frozen and stored at -80 °C until
the time of analysis.
HPLC analysis was performed with an ESA Model 5600A CoulArray® system
(ESA Inc., Chemlsford, MA, USA), equipped with Shimadzu Model DGU-14A on-line
degassing unit (Shimadzu Scientific Instruments, Columbia, MD, USA), an ESA Model
582 pump, and an ESA Model 542 refrigerated autosampler. The detection system
consisted of three coulometric array modules, and each contained four electrochemical
detector cells. Electrode potentials were selected over the range of +50 to +600 mV, with
a 50 mV increment against palladium electrodes. Chromatographic separation was
achieved by auto-injecting 20 μl sample aliquots at 5 ºC onto a MetaChem Intersil
(MetaChem Technologies, Torrance, CA, USA) reversed-phase C18 column (5 µm
particle size, 250 x 4.6 mm I.D.) with an ESA Hypersil C18 guard column (5 µm particle
size, 7.5 x 4.6 mm I.D.). The mobile phase used for compound separation consisted of 75
mM monobasic sodium dihydrogen phosphate, 2.0 mM SOS, 25 μM EDTA, 0.005%
triethylamine, and 10% acetonitrile, pH 3.0. A flow rate of 1.5 ml/min and analysis time
of 45 min were used for all experiments. System control and data acquisition/processing
were performed with ESA CoulArray software (version 1.02). All samples were
processed in technical triplicate, and median values used for statistical analysis.
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3.2.8

2-DG Autoradiography and CO Histochemistry

3.2.8.1 Tissue Collection
Adult (3–4 month) male hMT1 (N = 9) and hWT (N = 8) mice, along with WT (N
= 9) age- and gender-matched littermate controls, were used for quantitative analyses of
brain metabolism with 2-DG uptake and CO histochemistry.
After a single dose of 2-DG (0.165 μCi/g) given by intraperitoneal injection, mice
were placed in individual cages with free movement for 45 min to allow for 2-DG
absorption, overdosed with pentobarbital, and perfused with heparinized saline followed
by a mixture of 2.5% paraformaldehyde/1.5% glutaraldehyde/4% sucrose in 0.1 M PB.
Brains were rapidly removed from the skull, blocked, rapidly frozen in isopentane (-40
ºC), and stored at -80 ºC.
Brains were sectioned in five series on a cryostat at 20 μm in the coronal plane.
Sections were collected onto SuperFrost®-Plus glass slides and stored at -80 ºC in
vacuum-sealed slide containers. One series of sections was air-dried overnight and
stained with cresyl violet. Separate adjacent series were processed for 2-DG
autoradiography imaging and CO histochemistry.
3.2.8.2 Image Acquisition and Glucose Utilization (GU) Densitometric Analysis
Brain sections were exposed to Kodak Biomax MR Film together with 14C
Microscale™ autoradiography standards for 7 days. Autoradiographic images were
acquired in the transmission mode and were imported into ImageJ for ROI quantification
of radioactivity. Optical density (O.D.) was calibrated to the set of autoradiography
standards to generate measures of radioactivity for each ROI. ROIs were defined
according to a widely-employed mouse brain atlas (Franklin and Paxinos, 1997). Due to
potential confounding variables such as peritoneal absorption, blood-brain permeability,
and global utilization, ROI GU data from each mouse was converted to Z-scores.
3.2.8.3 CO Histochemistry
Our CO histochemistry protocol was modified from the protocol of GonzalezLima and Jones (1994). The reaction solution was freshly made in 0.1 M PB (pH. 7.4)
that contained 0.06% diaminobenzidine, 0.02% cytochrome c, and 4.5% sucrose. Brain
slides, together with brain-homogenate standards, were incubated in the reaction solution
for 1.5 h in the dark at 37 ºC in a shaking water bath. The reaction was stopped by
washing the slides with 0.1M PB with 4% sucrose for 3x 5 min. After dehydration in
ascending concentrations of ethanol (30%, 50%, 75%, 95%, and 2 X 100%), the slides
were cleared with xylene and were coversliped with Permount.
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3.2.8.4 Preparation of CO Standards and Biochemical Assay of CO Activity
Fresh whole brains from five wild-type C57BL/6J mice were homogenized with a
manual Dounce-glass homogenizer without buffer. The brain pastes were transferred to 2
ml microcentrifuge tubes. After centrifugation at 1000 rpm for 2 min at 4 ºC, the tubes
were rapidly frozen in prechilled isopentane (-40 ºC) and were stored at -80 ºC.
Brain pastes were sectioned on a cryostat in series of variable thickness that
covered the entire range of CO activities measured in different brain structures (5 μm, 10
μm, 20 μm, 30 μm, 40 μm, 50 μm, and 60 μm), collected onto SuperFrost®-Plus glass
slides, and stored at -80 ºC in a vacuum-sealed slide container for further usage as CO
activity standards.
The CO activity of the brain pastes was determined with a spectrophotometric
method modified from Hess and Pope (1953) by Gonzalez-Lima and Jones (1994). First,
the sample solution was generated by mixing the brain homogenate in 0.75%
deoxycholate solution at ratio of 0.01g per 5 ml. Next, 0.1 ml of the sample solution was
added to 0.9 ml of 30 μM reduced cytochrome c solution and mixed well. The O.D. was
measured with a SmartSpec3000 spectrophotometer (Bio-Rad Laboratories, Hercules,
CA, USA) at 550 nm with a kinetic program with 15 s intervals over a 3 min period. The
ΔO.D. was used for CO activity calculation with an extinction coefficient of 19000/Mcm. Each sample solution was read in triplicate and each homogenate was reacted 5
times. A measured mean activity of 30.02 mmol/min/g of tissue was used for subsequent
densitometric analyses.
3.2.8.5 CO Densitometric Analysis
Microscope slides were scanned with a Polaroid SprintScan 4000 (Polaroid
Corporation, Waltham, MA, USA) and PathScan Enabler (Meyer Instrument, Houston,
TX, USA) at a resolution of 2000 dpi along with brain-paste standards. The digital
images were imported into ImageJ for densitometry analysis, and the standards were used
to convert O.D. levels into enzyme activity values, reported as μmol/min/g of tissue for
each ROI. Due to considerable variations in raw ROI CO activity, CO activity within
each ROI was converted to Z-scores for subsequent statistical analysis.
3.2.9

Statistical Analyses

The results of all locomotor and biochemical experiments were analyzed by
means of one-way ANOVA using SAS. An alpha (α) of 0.05 was chosen for statistical
significance.
The results of 2-DG and CO histochemistry were analyzed with unpaired t-tests.
Data from hMT1 mice were compared to pooled data from hWT and WT mice, given that
(1) hWT mice express very low levels of human wild-type torsinA (data shown below),
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and (2) the high correlation of the data generated from hWT and WT mice (Pearson r =
0.98 for GU; Pearson r = 0.96 for CO activity). Because of the large number of
comparisons used in these experiments, the level of significance was set at 0.01 instead of
0.05. To evaluate networks altered by mutant torsinA, Pearson correlations were
calcuated for GU and CO activity in neuroanatomically-connected brain regions. The
ratios of CO activities and 2-DG signal densities were analyzed with unpaired t-tests.
3.3

RESULTS

3.3.1

TorsinA Expression in DYT1 Transgenic Mice

The transgenic expression of human torsinA was confirmed with Northern blot
analyses. As shown above in Figure 3-1C, human torsinA transcript appears as a 1.5 kb
band in transgenic mice and a 2.5 kb fragment in human brain. The expression of human
torsinA was robust in hMT1 mice, but was weak in hWT and hMT2 mice.
To extend the Northern blot results, QRT-PCR was performed with total RNA
from whole brain and striatum, along with species-specific primers and probes.
Cyclophilin D was used as an endogenous control. The amplification efficiencies of
human torsinA (1.99), mouse torsinA (1.98), human cyclophilin D (1.98) and mouse
cyclophilin D (1.97) were nearly identical.
The whole brain expression of human torsinA was measured in all three
transgenic lines relative to pooled human whole brain reference RNA, whereas
expression of human torsinA in the mouse striatum was referenced to RNA obtained
from a single human striatum. As shown in Table 3-2, hMT1 mice showed robust
whole-brain and striatal expression of human torsinA transcript (3.90X or 390% in the
whole brain and 4.95X or 495% in striatum). In contrast, hWT and hMT2 mice
expressed relatively low levels of human torsinA transcript. Due to the high level of
human mutant torsinA expression in hMT1 transgenic mice and the low level of mutant
torsinA expression in hMT2 mice, behavioral, morphological, neurochemical, and
metabolic studies were limited to the hMT1 transgenic line.
The relative expression of endogenous mouse torsinA transcript was calculated
for the three transgenic lines. Analysis of Table 3-2 indicated that the directions of
change in relative expression were the same for whole brain and striatum. In whole
brain, there were neither overall nor individual effects of genotype on relative levels of
mouse torsinA transcript. In striatum, although the effect of genotype on endogenous
torsinA expression was not significant (F3, 27 = 2.09, P = 0.130), individual comparisons
revealed a significant difference between endogenous torsinA expression in hWT and
hMT1 mice (F1, 27 = 6.21, P = 0.05).
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Table 3-2. Relative levels of human and mouse torsinA transcripts in DYT1
transgenic mice.
Whole Brain RNA
Line

Striatal RNA

Human
torsinA
transcript*

Mouse torsinA
transcript

Human
torsinA
transcript**

Mouse torsinA
transcript

hMT1

3.90 ± 0.451

1.14 ± 0.14

4.95 ± 0.34

1.33 ± 0.22

hMT2

0.07 ± 0.002

1.01 ± 0.02

0.07 ± 0.02

1.04 ± 0.06

hWT

0.04 ± 0.001

0.95 ± 0.07

0.05 ± 0.03

0.90 ± 0.05

WT littermates

--

1.01 ± 0.02

--

1.07 ± 0.04

Notes: *Relative to pooled RNA from 23 human brains. **Relative to striatal RNA from
a single human brain.
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3.3.2 Motor Dysfunction in DYT1 Transgenic Mice
The motoric abilities of transgenic mice were evaluated with a battery of tests that
included the raised-beam task, vertical-rope climbing, footprint analysis, and an
accelerating rotarod. In addition, we examined the response of transgenic mice to tail
suspension. In aggregate, these tests assessed several overlapping aspects of
sensorimotor function such as motor power, coordination, and postural stability.
There was no clear-cut evidence of dystonia in any of the mice. WT, hWT, and
hMT1 mice did not differ in their response to tail suspension. In particular, no mice
exhibited forepaw or hindpaw clasping within the 1-min period of observation. There
were no effects of genotype on either the accelerating rotarod (Figure 3-2A and B) or
vertical rope climbing (Figure 3-2C). However, there were significant effects of
genotype on footprint analysis and the raised-beam task (P < 0.05, for both). Compared
to WT and hWT mice, hMT1 showed increased hind-base width on footprint analysis (F1,
76 = 5.21, P = 0.025, Figure 3-2D) and prolonged traversal times on the 12-mm square
raised-beam task (F1, 53 = 18.85, P < 0.0001, Figure 3-2E). In follow-up raised-beam
task experiments, the effect of genotype on the 12-mm and 8-mm round-beam tasks was
significant for traversal times (F2, 37 = 5.62, P = 0.007; and F2, 37 = 3.52, P = 0.040;
respectively) and slip counts (F2, 37 = 3.55, P = 0.039; and F2, 37 = 5.45, P = 0.008;
respectively). Compared to WT mice, hMT1 mice demonstrated a 24% increase in
traversal times and a 425% increase in slip counts on the 12-mm round-beam task (P <
0.05, for both). As shown in Figure 3-2E and 3-2F, a 29% increase in traversal times
along with a 650% increase in slip counts were noted on the 8-mm round-beam task (P <
0.05, for both). The hWT mice also exhibited prolonged traversal times and more slips
on the round-beam tasks (P < 0.05, for all).
3.3.3

No Cytoplasmic Inclusion Bodies and Nuclear Envelope Vesicles Were
Found in DYT1 Transgenic Mice

Fluorescent immunocytochemistry was performed to search for ubiquitin- and/or
torsinA-positive cytoplasmic inclusion bodies in hMT1 mice. Although all brain regions
were surveyed, particular attention was focused on the pontine nuclei, cerebral cortex,
striatum, SNpc, and midbrain. The relative distribution of torsinA- and ubiquitin-IR did
not differ between hMT1 and WT mice (Figure 3-3). TorsinA- and ubiquitin-IR were
localized to the cytoplasm of neurons, but did not co-localize to cytoplasmic inclusions.
The subcellular localization pattern of torsinA-IR in hMT1 mice was similar to WT
littermates with no evidence of increased torsinA-IR surrounding the nuclear envelope.
Electron microscopy was used to search for ultrastructural abnormalities of the nuclear
envelope. In contrast to several other mouse models of DYT1 dystonia, we were unable
to identify bleb formation at the nuclear envelope in hMT1 mice (Figure 3-4).
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Figure 3-2. Behavioral analysis of motor functioning in DYT1 transgenic mice.
Performance of WT (filled circles or black bars), hWT (filled inverted triangles or gray
bars) and hMT1 (filled squares or dark gray bars) mice was quantitative analyzed in an
accelerating rotarod with increasing destination speeds (A); in an accelerating rotarod
with the same destination speed for five consecutive days (B); in vertical-rope climbing
(C); footprint analysis (D); and the raised beam task with 12-mm square-beam, 12-mm
round-beam, and 8-mm round-beam (E, F). Results are expressed as the mean ± SEM. *
denotes a significant difference between hMT1 and WT littermates (p < 0.05). + denotes
a significant difference between hMT1 and hWT littermates (p < 0.05). ** denotes a
significant difference between hWT and WT littermates (p < 0.05).

61

Figure 3-3. Cellular localization of torsinA and ubiquitin immunoreactivity in
neurons.
High-magnification confocal images of double-label fluorescent immunocytochemistry
for simultaneous detection of torsinA (green, right column gray scale) and ubiquitin (red,
middle column gray scale) in the pontine nuclei of hMT1, hWT and WT mice. No
obvious torsinA and ubiquitin-IR cytoplasmic inclusions or increased torsinA-IR in
nuclear envelope was found in hMT1. Double-label cells appear yellow in the merged
images. Scale bar, 25 µm.
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Figure 3-4. Electron microscopic images of the nuclear envelopes in DYT1
transgenic mice.
Electron microscopy was used to identify nuclear envelope blebs in the pontine nuclei,
cerebellum, spinal cord, and striatum of hMT1, hWT, and WT mice. There was no
nuclear envelope blebs (arrow) found in these regions. Scale bar, 1μm.
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3.3.4

Neurochemical Phenotype of DYT1 Transgenic Mice

In order to examine the possibility of a neurochemical imbalance in ΔGAG DYT1
transgenic mice, HPLC-EC was performed to quantify levels of monoamines and their
metabolites in striatum, cerebellum, and cerebral cortex. As seen in Figure 3-5, there
was a noteworthy effect of genotype on the level of DOPAC (F2, 28 = 4.89, P = 0.015) in
the cerebellum. Compared to WT mice, DOPAC was 59% higher (P = 0.026) in hMT1
mice. In cerebral cortex, a significant effect of genotype was apparent with respect to 5HT (F2, 28 = 3.87, P = 0.033). Compared to WT mice, 5-HT content was 98% higher (P
= 0.012) in hWT mice. Similarly, 5-HT content also tended to be higher in hMT1 than in
WT mice (76%, P = 0.054). In the striatum, significant effects of genotype were
observed for EPI (F2, 28 = 3.45, P = 0.046), DOPAC (F2, 28 = 4.99, P = 0.014), and
HVA (F2, 28 = 5.26, P = 0.012) levels. In comparison to WT mice, EPI, DOPAC, and
HVA levels were increased by 85% (P = 0.016), 58% (P = 0.004) and 76% (P = 0.007),
respectively, in hMT1 mice. Although there was no significant difference in striatal DA
content between hMT1 and WT mice, DA turnover (DOPAC/DA and HVA/DA) was
significantly higher in the mutants (P = 0.006 or both; Figure 3-6). To note, a significant
elevated level of DOPAC was also found in the cerebellum in hWT mice (P = 0.006).
3.3.5

Brain Metabolic Abnormalities in DYT1 Transgenic Mice

2-DG autoradiography as well as CO histochemistry was used to map brain
metabolic activity in hMT1, hWT, and WT mice. 2-DG autoradiography and CO
histochemistry provide complementary information regarding the glycolytic and
oxidative metabolism of the brain, in general. CO histochemistry is more specific for
neuronal activity, and readily demarcates the boundaries of neural structures.
Cytochrome c-oxidase (i.e., CO) is the terminal enzyme complex in the electron transport
chain of mitochondria. The regulation and assembly of CO requires a coordinated
interaction of the nuclear and mitochondrial genomes (Fontanesi et al., 2006). CO is
more specific for oxidative metabolism and more reflective of neuronal metabolic
demands that occurr over days to weeks (Di Rocco et al., 1989; Wong-Riley, 1989;
Gonzalez-Lima and Garrosa, 1991; Hevner et al., 1995). However, 2-DG is a glucose
analogue that has the 2-hydroxyl group replaced by a hydrogen so that it cannot undergo
glycolysis. Glucose hexokinase trapped 2-DG in most cells, which can be used as a good
marker for immediate tissue demand for glucose and its signal reflects both synaptic.and
neural activities (Wree and Schleicher, 1988; Wree, 1990; Duncan and Stumpf, 1991;
McCasland and Graczyk, 2001). In addition, the spatial resolution of CO histochemistry
is superior to 2-DG autoradiography.
3.3.5.1 CO Activity in DYT1 Transgenic Mice
The regional distribution of CO staining observed in WT mouse brain was similar
to the pattern that described for rat brain (Hevner et al., 1995). The highest densities of
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Figure 3-5. Quantitative HPLC-EC analysis of monoamines and their metabolites
in DYT1 transgenic mice.
Striatal, cerebral cortical, and cerebellar monoamines and their metabolites were analysed
in WT (black bars), hWT (gray bars), and hMT1 (dark gray bars) mice. DOPAC level
increase was observed in striatum and cerebellum of hMT1. Similarlly, HVA and EPI
level increases in hMT1 were observed in striatum. Results are expressed as the mean ±
SEM. * denotes a significant difference between hMT1 and WT littermates (P < 0.05).
+ denotes a significant difference between hMT1 and hWT littermates (P < 0.05). **
denotes a significant difference between hWT and WT littermates (P < 0.05).

65

Figure 3-6. Dopamine turnover in the striatum of DYT1 transgenic mice.
Dopamine turnover of WT (black bars), hWT (gray bars), and hMT1 (dark gray bars)
mice was expressed as DOPAC/DA and HVA/DA ratios. Striatal DOPAC/DA and
HVA/DA were significantly increased in hMT1. Results are expressed as the mean ±
SEM. * denotes a significant difference between hMT1 and WT littermates (P < 0.05).
+ denotes a significant difference between hMT1 and hWT littermates (P < 0.05).
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CO histochemical staining was found in cerebellar cortex, deep cerebellar nuclei, red
nucleus, caudate-putamen, subthalamic nucleus, and subregions of the cerebral cortex.
The lowest levels of CO histochemical staining were found in white matter (e.g., corpus
callosum) and neuronal populations with intermingled fiber pathways (e.g., globus
pallidus). In gray matter, the density of CO staining was not correlated with neuronal
density. For example, regions with dense neuronal packing such as the substantia nigra
pars compacta and granule cell layer of the dentate gyrus were weakly visualized with
CO histochemistry. Furthermore, compatible with the density of mitochondria at
synapses, some regions with a relative paucity of neuronal soma such as the molecular
layer in cerebellar cortex and stratum lacunosum-moleculare in hippocampus, showed a
relatively high CO staining. In some regions, the cellular patterns of CO staining were
quite distinctive. For example, in the red and vestibular nuclei, the majority of CO
staining was noted in the somas, whereas in the caudate-putamen and deep cerebellar
nuclei, neuronal soma and contiguous neuropil stained with similar intensity.
Densitometric analysis of CO activity in 55 neuroanatomical ROIs did not
identify a difference in whole brain CO activity between hMT1 and control mice.
However, after converting ROI CO activity to Z-scores, significant alterations in CO
activity were noted in individual neural structures. As seen in Table 3-3, significant
increases of CO activity were found in the inferior olive medial nucleus (IOM) and
Purkinje cell layer of cerebellar cortex in hMT1 mice in comparison with controls
,whereas significant decreases of CO activity were found in hMT1 caudal caudateputamen, substantia nigra pars reticulata and somatosensory 1 hindlimb in comparison
with controls.
3.3.5.2 GU in ROIs in DYT1 Transgenic Mice
Aggregate densitometric analysis of the 40 neuroanatomical ROIs showed that
whole-brain GU was similar between hMT1 and control mice. However, comparison of
individual ROI GU Z-scores revealed a significantly altered GU in several motor regions
of the brain. Z-scores of GU in the 40 ROIs and the respective statistical values are
presented in Table 3-4. In comparison to controls, hMT1 mice showed a significantly
increased GU in IOM, inferior olive dorsal accessory nucleus (IOD), and SNpc and a
significant reduced GU in medial globus pallidus (MGP) and lateral globus pallidus
(LGP).
3.3.5.3 Correlation Analysis
To provide additional interrogation of regional metabolic demand in the
sensorimotor regions of the brain (e.g., basal ganglia, cerebellum, and their input and
output nuclei), the correlation coefficients between anatomically-connected ROIs were
analyzed with Z-scores derived from CO histochemistry. Significant positive
correlations were noted between the interposed and red nuclei (0.54), medial cerebellar
and red nuclei (0.67), rostral caudate-putamen and LGP (0.74), rostral caudate-putamen
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Table 3-3. CO activity distribution in ROIs in DYT1 transgenic mice.
ROI
CPuC
SNR
IOM
PCL
S1HL
GL
VLG
MGP
ML
S1FL
IOD
Lat
Po
CPuRV
Rt
AInt
CPuRD
Med
BLA
DC
LGP
Cg
S1BF
CA3poly
IPC
M2
VP
LVe
M1
Pn
VL
S2
SO
SR
LSO
VM
CIC
MG
PAG
MVe

P
(Z-score)
0.0007
0.0033
0.0062
0.0077
0.0099
0.0110
0.0125
0.0141
0.0172
0.0234
0.0299
0.0385
0.0601
0.0765
0.0783
0.0838
0.0917
0.0951
0.1585
0.1633
0.1671
0.1951
0.2564
0.2760
0.3013
0.3666
0.3696
0.4113
0.4250
0.4540
0.4967
0.4974
0.5624
0.5775
0.5816
0.6569
0.6717
0.6852
0.6866
0.7003

CO activity (μmol/min/g)
Control
hMT1
41.43 ± 1.92 39.98 ± 2.64
24.61 ± 1.69 25.86 ± 2.06
20.15 ± 2.54 28.85 ± 2.17
35.53 ± 2.16 44.04 ± 2.94
35.19 ± 1.96 34.57 ± 2.57
27.26 ± 1.78 33.32 ± 2.49
28.7 ± 2.16
28.43 ± 2.12
15.83 ± 1.07 16.09 ± 1.34
31.17 ± 2.08 38.71 ± 2.67
34.94 ± 1.81 34.67 ± 2.54
19.77 ± 1.74 27.49 ± 2.16
35.38 ± 2.96 43.32 ± 3.69
31.92 ± 2.08 32.45 ± 3.1
41.33 ± 1.94 40.97 ± 2.95
25.61 ± 1.64 26.05 ± 2.35
33.51 ± 2.7
40.4 ± 3.86
31.48 ± 1.59 31.85 ± 2.42
21.67 ± 2.07 27.99 ± 2.8
33.93 ± 1.83 34.67 ± 3.08
26.33 ± 3.05 34.94 ± 4.26
23.86 ± 1.42 25.14 ± 2.09
33.9 ± 2.05
34.32 ± 2.64
33.93 ± 1.82 36.64 ± 3.02
29.13 ± 1.93 30.79 ± 3.05
28.46 ± 2.33 34.19 ± 2.62
31.66 ± 1.61 32.39 ± 2.4
34.64 ± 1.98 38.59 ± 3.19
20.38 ± 2.33 25.22 ± 2.2
34.13 ± 1.64 35.08 ± 2.86
15.33 ± 2.06 16.81 ± 1.98
24.91 ± 1.95 27.68 ± 2.45
30.23 ± 1.65 33.04 ± 2.63
28.71 ± 1.99 30.66 ± 2.86
26.15 ± 1.95 28.01 ± 2.61
30.4 ± 2.66
35.61 ± 3.47
26.65 ± 2.11 28.01 ± 2.34
39.22 ± 2.93 43.94 ± 4.21
30.79 ± 2.1
33.44 ± 2.72
24.6 ± 1.93
27.39 ± 2.29
23.84 ± 3.29 26.68 ± 4.56
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Z-score
Control
hMT1
1.47 ± 0.09
0.93 ± 0.1
-0.63 ± 0.05
-0.85 ± 0.05
-1.14 ± 0.18
-0.45 ± 0.15
0.74 ± 0.11
1.45 ± 0.2
0.67 ± 0.08
0.26 ± 0.11
-0.28 ± 0.09
0.11 ± 0.11
-0.12 ± 0.07
-0.5 ± 0.11
-1.72 ± 0.1
-2.06 ± 0.08
0.19 ± 0.1
0.77 ± 0.19
0.66 ± 0.07
0.28 ± 0.13
-1.18 ± 0.11
-0.6 ± 0.21
0.73 ± 0.19
1.3 ± 0.18
0.27 ± 0.09
-0.06 ± 0.13
1.45 ± 0.15
1.04 ± 0.16
-0.51 ± 0.07
-0.83 ± 0.15
0.5 ± 0.17
0.92 ± 0.16
0.22 ± 0.14
-0.09 ± 0.11
-0.95 ± 0.12
-0.62 ± 0.14
0.53 ± 0.11
0.25 ± 0.15
-0.35 ± 0.24
0.25 ± 0.33
-0.72 ± 0.09
-0.94 ± 0.12
0.53 ± 0.13
0.24 ± 0.17
0.64 ± 0.11
0.49 ± 0.06
-0.08 ± 0.1
-0.24 ± 0.11
-0.07 ± 0.17
0.21 ± 0.2
0.37 ± 0.12
0.17 ± 0.17
0.63 ± 0.08
0.74 ± 0.09
-1.1 ± 0.14
-0.93 ± 0.14
0.69 ± 0.14
0.49 ± 0.19
-1.74 ± 0.12
-1.95 ± 0.23
-0.6 ± 0.1
-0.49 ± 0.11
0.18 ± 0.13
0.05 ± 0.13
-0.14 ± 0.11
-0.24 ± 0.15
-0.46 ± 0.13
-0.57 ± 0.15
0.18 ± 0.2
0.38 ± 0.28
-0.39 ± 0.1
-0.43 ± 0.04
1.23 ± 0.25
1.38 ± 0.26
0.15 ± 0.12
0.09 ± 0.1
-0.61 ± 0.08
-0.66 ± 0.08
-0.66 ± 0.25
-0.82 ± 0.34

Table 3-3. (Continued).
ROI
H
PnO
InG
LD
oDG
RMC
STh
SLM
DLG
RMg
VA
APTD
LC
iDG
SuG

P
(Z-score)
0.7014
0.7136
0.7151
0.7523
0.7837
0.8130
0.8254
0.8510
0.8533
0.8642
0.8840
0.9249
0.9434
0.9576
0.9897

CO activity (μmol/min/g)
Control
hMT1
23.76 ± 1.77 26.18 ± 2.83
23.93 ± 2.01 27.42 ± 2.17
30.84 ± 2.2
33.11 ± 3.04
29.4 ± 2.45
31.91 ± 2.75
27.46 ± 2.26 30.07 ± 2.47
37.59 ± 1.91 41.37 ± 2.91
45.46 ± 2.83 48.49 ± 3.17
47.88 ± 2.72 50.19 ± 3.61
30.58 ± 2.21 33.17 ± 2.62
14.08 ± 1.24 17.13 ± 1.98
30.58 ± 2.37 32.15 ± 2.51
29.76 ± 2.19 32.6 ± 2.84
23.39 ± 2.14 26.58 ± 2.59
34.61 ± 2.36 37.44 ± 3.33
27.45 ± 2.02 30.31 ± 3.11
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Z-score
Control
hMT1
-0.74 ± 0.1
-0.81 ± 0.14
-0.71 ± 0.08
-0.66 ± 0.1
0.14 ± 0.1
0.06 ± 0.18
-0.04 ± 0.1
-0.09 ± 0.13
-0.26 ± 0.12
-0.31 ± 0.09
1.04 ± 0.19
1.13 ± 0.33
1.95 ± 0.11
1.99 ± 0.16
2.26 ± 0.15
2.22 ± 0.15
0.1 ± 0.08
0.08 ± 0.1
-1.9 ± 0.1
-1.93 ± 0.12
0.09 ± 0.1
0.11 ± 0.06
-0.01 ± 0.08
0.01 ± 0.14
-0.78 ± 0.11
-0.77 ± 0.13
0.58 ± 0.14
0.59 ± 0.13
-0.29 ± 0.13
-0.29 ± 0.2

Table 3-4. GU distribution in ROIs in DYT1 transgenic mice.
ROI
MGP
IOM
IOD
SNpc
LGP
VM
IPC
STh
Lat
RMCR
CHem
CVer
S2
SO
Med
Cg
PAG
VL
SuG
AInt
IC
M1
SNR
Pn
M2
RMCC
PnO
S1BF
CPuRV
LC
Mve
RMg
VP
CPuC
DC
VA
S1HL
CPuRD
LVe
S1FL

P
(Z-score)
0.0011
0.0018
0.0063
0.0077
0.0097
0.0226
0.0265
0.0430
0.0745
0.0863
0.1134
0.1158
0.1719
0.1743
0.1972
0.2290
0.2423
0.2446
0.2881
0.3113
0.3603
0.3666
0.4315
0.4436
0.5350
0.5357
0.5581
0.5738
0.6788
0.7010
0.7422
0.7548
0.7591
0.8067
0.8361
0.9079
0.9513
0.9768
0.9897
0.9921

GU (nCi/g)
control
hMT1
164.84 ± 11.91 154.64 ± 12.09
225.91 ± 13.23 269.48 ± 18.13
183 ± 13.41
220.78 ± 14.27
235.33 ± 14.85 271.21 ± 16.43
184.25 ± 11.95 182.5 ± 14.19
282.09 ± 16.73 321.88 ± 18
305.68 ± 20.73 305.04 ± 20.69
284.99 ± 16.96 295.72 ± 19.07
286.87 ± 16.52 320.02 ± 20.51
283.83 ± 16.57 294.31 ± 21.4
224.74 ± 13.66 251.99 ± 16.94
240.14 ± 12.99 270.75 ± 17.24
269.37 ± 15.03 281.07 ± 16.75
350.22 ± 17.8
346.05 ± 18.6
273.69 ± 15.92 303.08 ± 19.09
271.43 ± 15.95 279.64 ± 21.04
150.44 ± 10.3
157.52 ± 13.81
256.73 ± 15.8
286.89 ± 17.51
226.78 ± 17.49 232.41 ± 17.57
290.78 ± 16.6
320.08 ± 22.12
500.71 ± 24.13 546.82 ± 41.84
254.09 ± 14.81 277.18 ± 17.29
176.44 ± 15.04 183.86 ± 16.81
178.05 ± 15.44 200.94 ± 18.82
283.14 ± 15.73 300.19 ± 20.64
281.25 ± 17.8
296.72 ± 21.16
220.91 ± 17.16 243.15 ± 16.44
320.91 ± 16.57 338.78 ± 19.07
258.39 ± 16.79 271.97 ± 15.75
230.53 ± 14.07 256.78 ± 21.73
323.03 ± 18.28 349.86 ± 24.12
235.12 ± 16.58 250.19 ± 17.96
318.19 ± 17.07 337.13 ± 17.19
251.74 ± 14.78 271.14 ± 14.94
306.96 ± 16.08 325.65 ± 24.74
339.91 ± 19.22 362.17 ± 17.83
264.41 ± 14.87 285.63 ± 22.4
274.32 ± 14.68 294.23 ± 17.14
330.62 ± 19.6
351.85 ± 20.72
267.1 ± 14.73
287.52 ± 18.82
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Z-score
control
-1.53 ± 0.06
-0.59 ± 0.07
-1.26 ± 0.08
-0.46 ± 0.08
-1.22 ± 0.06
0.26 ± 0.06
0.61 ± 0.11
0.3 ± 0.05
0.33 ± 0.08
0.28 ± 0.03
-0.61 ± 0.04
-0.37 ± 0.06
0.08 ± 0.07
1.32 ± 0.13
0.13 ± 0.09
0.1 ± 0.11
-1.73 ± 0.08
-0.13 ± 0.08
-0.61 ± 0.12
0.39 ± 0.07
3.56 ± 0.09
-0.17 ± 0.06
-1.37 ± 0.09
-1.34 ± 0.09
0.28 ± 0.09
0.23 ± 0.07
-0.68 ± 0.08
0.87 ± 0.08
-0.11 ± 0.1
-0.5 ± 0.1
0.87 ± 0.08
-0.45 ± 0.12
0.81 ± 0.08
-0.21 ± 0.08
0.63 ± 0.11
1.13 ± 0.07
0 ± 0.09
0.15 ± 0.09
0.97 ± 0.07
0.04 ± 0.09

hMT1
-1.88 ± 0.06
-0.22 ± 0.07
-0.93 ± 0.07
-0.2 ± 0.04
-1.49 ± 0.07
0.56 ± 0.1
0.29 ± 0.07
0.15 ± 0.04
0.5 ± 0.04
0.12 ± 0.08
-0.48 ± 0.06
-0.21 ± 0.08
-0.05 ± 0.05
0.92 ± 0.24
0.26 ± 0.03
-0.09 ± 0.11
-1.85 ± 0.06
0.07 ± 0.14
-0.76 ± 0.07
0.49 ± 0.06
3.73 ± 0.15
-0.1 ± 0.05
-1.47 ± 0.09
-1.23 ± 0.1
0.21 ± 0.06
0.16 ± 0.09
-0.61 ± 0.09
0.79 ± 0.09
-0.17 ± 0.1
-0.43 ± 0.17
0.93 ± 0.14
-0.51 ± 0.13
0.78 ± 0.08
-0.18 ± 0.08
0.58 ± 0.21
1.16 ± 0.16
-0.01 ± 0.09
0.14 ± 0.04
0.97 ± 0.08
0.04 ± 0.07

and MGP (0.64), and LGP and MGP (0.77) in control but not hMT1 mice. In addition,
significant negative correlations were noted between rostral caudate-putamen and
subthalamic nucleus (STh; -0.70), and MGP and STh (-0.51) in control but not in hMT1
mice (Table 3-5). The loss of correlations indicated the functional abnormalities in these
pathways in hMT1 mice.
3.4

DISCUSSION

Several murine models of DYT1 dystonia have been developed and characterized
to varying degrees (Dang et al., 2005, Goodchild et al., 2005; Sharma et al., 2005;
Shashidharan et al., 2005; Dang et al., 2006; Grundmann et al., 2007; Table 1-2).
Although some common themes exist among these models, substantial discordance has
been apparent in morphological findings, and robust behavioral and neurochemical
characterizations have been largely incomplete. In our study, detailed genetic,
behavioral, morphological, neurochemical, and brain metabolical analyses were
performed in a human ΔGAG transgenic mouse model of DYT1 dystonia. Our results
demonstrated a high-level mutant transgene expression in hMT1 mice, in addition to
distinct motor, neurochemical, and brain metabolical abnormalities in the hMT1 line.
These findings demonstrate that the human mutant torsinA transgenic mouse (hMT1) is a
valid model for the study of DYT1 dystonia. Of utmost importance, our results indicate
that defective nigrostriatal signaling, as demarcated with an increased striatal DA
turnover might be critical to the pathobiology of DYT1 dystonia.
Transgenic models of DYT1 dystonia have been developed by Sharma et al.
(2005), Shashidharan et al. (2005), and Grundmann et al. (2007). Using quantitative
analysis of Western blots, Sharma and colleagues (2005) showed that hMT1, hMT2, and
hWT transgenic mice express torsinA at 2.1X, 1.3X, and 2.3X that of WT littermates.
Similarly, Shashidharan and co-workers (2005) showed an increased torsinA protein
expression in four transgenic lines (TG#13, TG#22, TG#35, and TG#49). In more recent
work, Grundmann and colleagues (2007) analyzed normal and mutant human torsinA
transgene expression at the transcript and protein levels. Human torsinA transcript levels
were referenced to the hWT24 line of mice. The largest fold increase in transcript levels
was noted in the hΔGAG3 line of torsinA mutant mice (1.30X). In a more functional
assay, we showed that striatal torsinA transcript expression was 3.90X higher in hMT1
mice than in human brain. Because current thinking indicates that a single mutant
torsinA molecule can disrupt assembly of a mature hexameric molecular motor
(Breakefield et al. 2001), stoichiometric considerations would suggest that an increase in
the cellular burden of mutant torsinA would decrease the probability of hexamer
formation. Apparently, a minimal number of functional torsinA hexamers are required
for normal neural function and organismal survival because DYT1 knockout and
homozygous DYT1 knock-in mice die shortly after birth (Goodchild et al. 2005).
Therefore, robust transgenic expression of mutant torsinA as seen in hMT1 mice might
be the most viable means to model human DYT1 dystonia.
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Table 3-5. Pearson correlations between neuroanatomically-connected nuclei in DYT1 transgenic mice.
ROI
AInt / RMC
Med / RMC
RVCPu / LGP
RVCPu / MGP
RVCPu / STh
RDCPu / LGP
RDCPu / MGP
RDCPu / STh
CCPu / LGP
CCPu / MGP
LGP / MGP
MGP / STh
Lat / IOM

Control
r
P (r)
0.54
0.0264
0.67
0.0036
0.74
0.0007
0.64
0.0061
-0.7
0.0017
0.83
<0.0001
0.79
0.0001
-0.7
0.0016
0.72
0.0012
0.5
0.0399
0.77
0.0003
-0.51
0.0364
0.59
0.0134

CO Activity
hMT1
r
P (r)
-0.01
0.9818
-0.51
0.1574
0.56
0.117
0.44
0.234
0.28
0.463
0.36
0.3401
0.48
0.1899
-0.13
0.7389
0.84
0.0044
0.69
0.0395
0.63
0.0668
0.4
0.2918
0.13
0.7463

P
(Ratio)
0.2335
0.1151
0.1579
0.5142
0.1109
0.4022
0.6819
0.2526
0.0213
0.2707
0.5528
0.3354
0.0243

2-DG Autoradiography
Control
hMT1
r
P (r)
r
P (r)
0.22
0.4503
0.48
0.2312
0.21
0.4802
0.38
0.3522
0.22
0.45
-0.03
0.944
0.06
0.8348
-0.67
0.0703
-0.47
0.0934
-0.77
0.0244
0.25
0.3888
-0.05
0.9054
0.04
0.8863
-0.49
0.2181
-0.6
0.0232
-0.63
0.0937
0.19
0.5075
-0.79
0.0189
0.13
0.6525
-0.39
0.3446
0.49
0.0738
0.39
0.3338
0.03
0.9187
0.46
0.2481
0.1
0.7258
0.32
0.4358

P
(Ratio)
0.0412
0.0298
0.1676
0.0867
0.6592
0.0593
0.0257
0.6592
0.1038
0.0264
0.2189
0.0211
0.0406

Notes: r, pearson correlation coefficient; P (r), significant value for the correlation coefficient; P (Ratio), significant value for
the ratios between the two groups.
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Genetically engineered mice cannot accurately model all of the molecular,
cellular, and physiological features of human neurogenetic disorders. Individual models
have their own distinct limitations and utilities. In transgenic models, the promoter,
construct design and insertion site dictate the temporal and spatial regulation of transgene
expression. Moreover, transgenic models might be associated with locus-specific
insertional effects. In a comparative analysis of torsinA transgenic models, several points
must be considered. First, utilization of a neuron-specific promoter like neuron-specific
enolase precludes consideration of glial-specific and glial-neuronal interactions as
contributors to the pathophysiology of DYT1 dystonia (Shashidharan et al., 2005).
Furthermore, the mice generated by Shashidharan and colleagues (2005) exhibited
bizarre circling behavior that is not seen in other murine models of DYT1 dystonia. In
the transgenic mice generated by Grundmann et al. (2007), the expression of mutant
torsinA that contained a V5-his tag was driven by the murine prion protein promoter
(Grundmann et al., 2007). It is possible that even a small V5-his tag could interfere with
one or more functional properties of torsinA. In contrast to other transgenic models of
DYT1 dystonia, the expression of untagged mutant torsinA in hMT1 mice is driven by
the cytomegalovirus (CMV) promoter, which is well-known for its ability to drive
widespread transgene expression (Boshart et al., 1985; Sharma et al., 2005).
Similar to other models of DYT1 dystonia, none of the transgenic mice used in
our study (hMT1, hMT2, and hWT) showed overt evidence of dystonia. The response of
hMT1 mice to tail suspension and performance on vertical-rope climbing and the
accelerating rotarod were all similar to WT littermates. However, hMT1 mice exhibited
a mildly abnormal motor phenotype characterized by an increased hind-base width and an
impaired performance on the raised-beam task. These findings are consistent with
previous reports of heterozygous DYT1 knock-in and DYT1 knock-down mice (Dang et
al., 2005; 2006), as well as hWT24 transgenic mice (Grundmann et al., 2007). DYT1
knock-in mice display an abnormal gait with a significant overlap in paw placement, as
well as motor coordination deficits on the raised-beam task (Dang et al., 2005). DYT1
knock-down mice also demonstrated motor-coordination deficits on the raised-beam task
(Dang et al., 2006). The raised-beam task integrates multiple components of the
sensorimotor system, and has been used for functional evaluation of the nigrostriatal
pathway (Dluzen et al., 2001) and to estimate the deficits induced by sensorimotor cortex
ablation (Goldstein & Davis, 1990) and ischemic stroke (Brown et al., 2004). The raisedbeam task has also been used to characterize motor dysfunction in murine models of
"basal ganglia" disorders such as Huntington and Parkinson diseases (Carter et al., 1999;
Strome et al., 2006). Because abnormalities in dopaminergic neurotransmission in mice
have been associated with hypoactivity, stride-length reduction, and poor performance on
the raised-beam task, an explanation for the motor abnormalities of hMT1 transgenic
mice might be derived, in part, from the observed increase in striatal DA turnover
(Dluzen et al. 2001; Fernagut et al. 2002; 2003).
Footprint analysis is another useful tool used to evaluate motor and gait
abnormalities in murine models of movement disorders. Footprint analysis along with
digital surrogates have been used to examine gait alterations induced by striatal damage
(Teunissen et al., 2001), genetic defects of Purkinje cells (Jiao et al., 2005), sensory
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neuropathy (Wietholter et al., 1990), and diffuse cerebral disease (McGavern et al.,
1999). As is the case for human gait disorders, distinct footprint patterns can be ascribed
to lesions of specific neural subsystems in mice. Animals with cerebellar defects, for
instance, often display considerable increases in front- and hind-base widths (Wietholter
et al., 1990; Jiao et al., 2005). In agreement with functional-imaging studies, the
increased hind-base width noted in hMT1 mice suggested that mutant torsinA might
contribute to cerebellar dysfunction in humans with DYT1 dystonia (Carbon et al.,
2004a).
Work in Drosophila suggests that torsinA could play a role at the mammalian
neuromuscular junction (Koh et al., 2004). In our study, the performance of torsinA
mutant mice on vertical-rope climbing does not entirely dismiss this possibility because
hMT1 mice tended to perform worse than WT littermates. Vertical-rope climbing
requires substantial motor strength, and is likely to illicit abnormalities in mice with
disorders of muscle, the neuromuscular junction, or anterior horn cells (Anderson et al.,
2005).
Unlike two previous studies with torsinA transgenic mice, we were unable to
identify rotarod abnormalities in either hMT1 or hWT mice (see Table 1-2). In this
regard, several points are worthy of note. First, Grundmann et al. (2007) employed 6month old mice and Sharma and colleagues (2005) only found rotarod abnormalities in
mice at 9 months of age. In contrast, our studies were performed in much younger adult
mice. Second, Sharma et al. (2005) pooled results from hMT1 and hMT2 mice, whereas
we restricted our behavioral experiments to hMT1 mice. Finally, all of our experiments
were performed with mice backcrossed (C57BL/6J) at least 8 generations, whereas
Sharma et al. (2005) combined F5 and F6 progeny for their experiments. Grundmann et
al. (2007) did not comment on the genetic uniformity of their mice. In this context, it
should be emphasized that our hWT mice are not a viable model of human wild-type
torsinA overexpression. Similarly, with regards to the hMT2 mice, it is likely that mutant
transgene expression is too low to significantly disrupt cellular pathways that are
dependent on torsinA. It is possible that transgene repression or inactivation, which has
been described in numerous plant and animal models, is responsible for the Northern blot
and QRT-PCR results seen in hWT and hMT2 mice (Kilby et al., 1992; ChevalierMariette et al., 2003; Thomas et al. 2005). DNA methylation, which might occur over
several generations, appears to be the most common mechanism of transgene
repression/inactivation.
Although to a lesser degree than the hMT1 mice, the hWT line of mice also
exhibited prolonged traversal times and more slips on the round raised-beam tasks.
These abnormalities in the hWT mice might be an insertional effect of the transgene since
expression of the wild-type torsinA was negligible in these mice. Alternatively, a
deleterious effect of small amounts of wild-type human torsinA cannot be excluded since
Grundmann and colleagues also noted behavior abnormalities in mice expressing wildtype human torsinA (Grundmann et al., 2007).
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Laser-scanning confocal and electron microscopy were used to search for cellular
and ultrastructural abnormalities in torsinA transgenic mice. Our results are compatible
with the initial report of Sharma and colleagues (2005), but differ from findings in other
DYT1 transgenic, knock-in, and knock-out models. (Shashidharan et al., 2005; Dang et
al., 2005; Goodchild et al., 2005; Grundmann et al., 2007). Morphological analysis of
other DYT1 models has revealed ubiquitin- and torsinA-positive cytoplasmic inclusion
bodies (Shashidharan et al., 2005; Dang et al., 2005; Grundmann et al., 2007), as well as
bleb formation at the nuclear envelope (Goodchild et al., 2005; Grundmann et al., 2007;
Table 1-2). It is likely that technical factors related to tissue processing, rodent age, and
relative cytoplasmic concentration of endogenous torsinA contributed to the appearance
of cytoplasmic inclusions and nuclear envelope bleb formation. Because DYT1 dystonia
rarely appears after 28 years of age, we chose to use young adult mice for our studies.
Because inclusion formation in most neurodegenerative diseases is closely tied to the
aging process, our failure to detect cytoplasmic inclusions in young adult mice is not
surprising. With regard to nuclear envelope bleb formation, it should be emphasized that
our mice were perfused with a fixative (4% paraformaldehyde/2.5% glutaraldehyde/15%
picric acid), which is well-known to preserve ultrastructural morphology. Marked
reduction in functional torsinA is also required for the appearance of nuclear envelope
blebs because structural abnormalities of the nuclear envelope were described in
homozygous DYT1 knock-in and knock-out mice, but not in their heterozygote DYT1
littermates (Goodchild et al., 2005). In aggregate, motor and neurochemical
abnormalities were observed in DYT1 models that demonstrated cellular pathology, as
well as in those that do not. Thus, causal relationships among morphological, motor, and
neurochemical phenotypes remain unclear.
To investigate the possibility of a neurochemical abnormality in torsinA mutant
mice, we performed HPLC-EC analysis of monoamine transmitters and their metabolites.
The most striking findings were significantly increased DOPAC/DA and HVA/DA ratios
(measures of DA turnover) in hMT1 striatum. Increases in DOPAC/DA and HVA/DA
turnover can manifest from a number of scenarios, including an increased DA release, a
decreased DA uptake due to abnormal functioning of the dopamine and/or vesicular
monoamine transporters, or an increased monoamine oxidase (MAO) activity. Our
findings in DYT1 transgenic mice are compatible with previous neuroimaging and
postmortem neurochemical studies of human DYT1 dystonia. For example, Augood and
colleagues (2002) observed a significantly increased DOPAC/ DA ratio, along with a
trend toward reduction in D1 and D2 receptor binding in the striatum of human
postmortem DYT1 dystonia brains. A corresponding decrease in striatal D2 receptor
binding has been described in non-manifesting DYT1 mutation carriers (Asanuma et al.,
2005). Increased striatal DA turnover and down-regulation of striatal D2 receptors
suggests that functional and/or morphological anomalies of the nigrostriatal pathway
might be important to the pathobiology of DYT1 dystonia.
Quite variable results have been reported from the neurochemical analyses of
other DYT1 mouse models (Table 1-2). In transgenic mice generated by Shashidharan
and colleagues (2005), decreased striatal DA levels were observed in mice with motor
abnormalities (i.e., “affected” mice), whereas increased striatal DA levels were detected
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in mice without motor abnormalities (i.e., “unaffected” mice). Despite these differences
in absolute DA levels, DOPAC/DA ratios were decreased in “affected” and “unaffected”
mice compared to wild-type controls; those data suggested an overall decrease in DA
turnover (Shashidharan et al., 2005). In heterozygote DYT1 knock-in mice, striatal HVA
levels were found to be significantly decreased with no alterations of DA and DOPAC
content (Dang et al., 2005), and DYT1 knock-down mice demonstrated significantly
reduced DOPAC levels, with only a slight decrease in striatal DA (Dang et al. 2006). In
addition to decreased striatal DA, decreases in 5-HT and 5-HIAA were also noted in the
hWT transgenic mice generated by Grundmann and colleagues (2007). In the brainstem
only, a decrease in HVA levels and an increase in DOPAC, 5-HT and 5-HIAA levels
were noted in hΔGAG3 transgenic mice (Grundmann et al., 2007). Taken together, these
mixed neurochemical findings in DYT1 mouse models suggest that mutant and WT
torsinA can both influence striatal dopaminergic neurotransmission.
GU and CO activity serve as surrogate and indirect markers of acute and chronic
metabolic activities in the brain. The systems-level information derived from metabolic
mapping can be integrated with behavioral, neurochemical, and electrophysiological
alterations in DYT1 mice. For comparisons with hMT1 mice, the control group included
data from WT and hWT mice because hWT show negligible transgene expression, and
ROI GU and CO activity from hWT and WT were highly correlated. CO activity was
significantly increased in the IOM and Purkinje cell layer of cerebellar cortex and
decreased in caudal caudate-putamen, SNR, and S1HL of hMT1 mice in comparison to
the control group. Similarly, GU was significantly increased in IOM, IOD, and SNC, and
was decreased in MGP and LGP in hMT1 mice.
Given that GU and CO activity measure distinct metabolic processes on different
time scales, it is not surprising that these two metabolic mapping methods generated both
overlapping and unique results. Similar inconsistencies between GU and CO metabolic
patterns have also been reported in the mutant dystonic hamster (Nobrega et al., 1998,
Richter et al., 1998). Moreover, functional neuroanatomical studies have shown that
measures of GU and CO activity capture different aspects of network activity (Jacquin et
al., 1993). As noted, signals derived from CO histochemistry are concentrated at sites
with mitochondrial density, whereas the signals of 2-DG autoradiography predominate at
axon terminals with high Na+-K+-ATPase activity (Di Rocco et al., 1989).
Overall, functional brain mapping in hMT1 mice demonstrated a shift of
metabolic demand from the basal ganglia to the cerebellum. In the basal ganglia, the
decreased GU noted in the MGP and LGP might be due, in part, to decreased CO activity
in CPu neurons, which send GABAergic projections to MGP, LGP, and SNR. In MGP
and SNR, CO was also reduced. In agreement with these findings, independent studies in
human subjects with generalized and focal dystonias have found significantly reduced
mean GPi firing rates (Starr et al., 2005; Tang et al., 2007). These changes in CO activity
in MGP and SNR mirror complicated results in the dystonic hamster (Nobrega et al.,
1998). Although likely associated, our approach does not allow us to ascribe the hMT1
metabolic abnormalities in the basal ganglia to the increased nigrostriatal dopaminergic
turnover in hMT1 mice.
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Interestingly, hypermetabolism in the cerebellar hemispheres has been reported in
non-manifesting DYT1 carriers (Eidelberg, 1998; Trost et al., 2002; Carbon et al.,
2004a). Compatible with these clinical results, we identified hypermetabolism in the
Purkinje cell layer (PCL) of cerebellum in hMT1 mice. In our model, increased GU/CO
activity in the inferior olive, which sends excitatory input to cerebellar Purkinje cells via
the climbing fiber pathway, might alter the firing properties of Purkinje cells-as has been
described in the dt rat (LeDoux and Lorden, 2002). Elevated Purkinje cell firing rates
would be associated with an enhanced metabolic activity at GABAergic synaptic
terminals in the cerebellar nuclei; similar results have been identified in the dt rat
(Ledoux, 2004). Although it is not possible to specifically attribute the gait abnormalities
in hMT1 mice to dysfunction of either the basal ganglia or cerebellum, increased
hindbase width is classically associated with dysfunction of the latter. Theoretically, this
cerebellar abnormality could be primary or secondary to dysfunction of the basal ganglia.
However, in DYT1 carriers, functional imaging suggests the primary dysfunction of the
basal ganglia leads to compensatory maladaptive neural output from the cerebellum
(Ghilardi et al., 2003; Carbon et al., 2008b).
The inferior olive may play a central node in communication between the basal
ganglia-thalamocortical and olivocerebellar circuits (Alexander and Crutcher, 1990;
Marshall and Lang, 2004). The inferior olive receives a wide variety of excitatory and
GABAergic projections (Walberg, 1956, , 1974; Berkley and Hand, 1978; Berkley and
Worden, 1978; Saint-Cyr and Courville, 1981; Swenson and Castro, 1983). Inferior
olivary afferents arise from the spinal cord, medulla, pons, midbrain, cerebellar nuclei,
and cerebral cortex. Projections from the red nucleus, periaqueductal gray, and other
midbrain nuclei such as the interstitial nucleus of Cajal, nucleus of Bechterew, and
nucleus of Darkschewitsch enter the central tegmental tract, descend uncrossed, and
terminate in the inferior olive. Fibers, which ascend in the spinal cord, reach the inferior
olive either directly through the spino-olivary tract that courses through the anterior
funiculus or indirectly via the dorsal column nuclei. Dysfunction of one or more of these
afferents might induce hypermetabolism and altered neuronal activity in the IO.
Alternatively, a defect intrinsic to the IO could be causally associated with
pathophysiology of DYT1 dystonia because climbing fiber dysfunction is critical to the
dystonic movement disorders of the dt rat and rats treated with the neurotoxin 3acetylpyridine (Sukin et al., 1987; Ledoux, 2004).
With a 2-DG autoradiography protocol similar to our own, striking increases in
GU were detected in the cerebellar nuclei of the dt rat (Brown and Lorden, 1989). In the
dt rat, correlations for GU in regions with known anatomical connections also suggested
that basal ganglia efferents might be abnormal. The GU metabolism pattern identified in
hMT1 transgenic mice show important qualitative similarities to patterns described in dt
rats. However, the magnitude of the changes in hMT1 mice was small relative to
alterations seen in the dt rat-probably due to the fact that the latter model exhibits a
profound generalized dystonia. Clearly, the cerebellum contributes to the dystonic
movement disorder of the dt rat, which is eliminated by cerebellectomy (LeDoux et al.,
1993; LeDoux et al., 1995).
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Our correlation analysis supports the validity of our findings. In particular, the
correlations that we obtained in control mice are similar to values previously reported in
hamsters and rats (Brown and Lorden, 1989; Richter et al., 1998). For specific examples,
mice, rats, and hamsters show positive correlations between the cerebellar nuclei (medial
and interpositus) and the red nucleus. In addition, positive correlations between the
striatum and LGP have been described in all three species of rodents. These and several
other correlations in control mice, including positive correlations of rostral caudateputamen to MGP, negative correlations of rostral caudate-putamen to subthalamic
nucleus, and negative correlations of MGP to STh, were disrupted in hMT1 mice.
Reduced GPi output to the thalamus might result in enhanced thalamocortical
activation. In similar fashion, reduced SNR output might result in enhanced activity in
the tectal and tegmental pathways, which receive inhibitory projections from SNR.
Clearly, DYT1 dystonia is a network disorder of similar topography among manifest and
non-manifest carriers of the ΔGAG mutation.
3.5

CONCLUSIONS

In summary, our study has provided a vigorous analysis of the genetic, motoric,
morphological, neurochemical, and brain metabolic features of the hMT1 transgenic
mouse model of DYT1 dystonia. The hMT1 model exhibits distinct motor,
neurochemical, and brain metabolical phenotypes that result from the cellular burden of
mutant torsinA. The increased DA turnover identified in hMT1 mice is noteworthy
because tetrabenazine, a dopamine-depleting drug, has been used successfully in patients
with generalized dystonia (Jankovic and Orman, 1988). Furthermore, mutant torsinA
appears to interfere with the dopamine and vesicular monoamine transporters (Torres et
al., 2004; Cao et al., 2005; Misbahuddin et al., 2005). Thus, the hMT1 mouse might be
used to study the systems and cellular biology of torsinA and to evaluate potential
therapeutics for DYT1 dystonia.
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CHAPTER 4. SUMMARY AND DISCUSSION
4.1

SUMMARY

In the research presented in the dissertation, the systems biology of torsinA was
examined with two approaches. First, perturbation models were used to examine the
systems biology of torsinA. Transient forebrain ischemia was used as a CNS
perturbation and sciatic nerve transection as a PNS perturbation. The temporal and
spatial responses of torsinA transcript and protein expression in neural tissues were
evaluated with QRT-PCR, in situ hybridization, and immunohistochemistry. Upregulation of torsinA expression in neural tissues was found after central and peripheral
insults. The initial up-regulation of torsinA transcript after ischemia was localized to the
major neuronal populations that expressed high levels of torsinA even in the control
tissues. However, the delayed component of torsinA up-regulation included prominent
expression in reactive astrocytes in regions of hippocampus (e.g., CA1) known to
undergo neuron loss and synaptic reorganization after ischemia. The up-regulation of
torsinA in DRG showed similar temporal and spatial patterns to the CNS. Up-regulation
of torsinA was detected in ganglion cells and satellite cells in ipsilateral DRG; however,
torsinA was preferentially concentrated in satellite cells in the contralateral DRG. Our
perturbation models have provided the first descriptions of torsinA expression in reactive
glial elements. Overall, our findings suggest that torsinA participates in the response of
neural tissue to central and peripheral insults. Moreover, the sustained up-regulation of
torsinA in interneurons and reactive astrocytes in the regions with significant neuron loss
and putative synaptic reorganization indicates that torsinA might contribute to the
remodeling of neuronal circuitry. In addition, the striking induction of torsinA in
astrocytes and satellite cells points to the potential involvement of glial elements in the
pathobiology of DYT1 dystonia.
DYT1 transgenic mouse models were used to examine the systems biology of
torsinA. We performed an analysis of the motor behavioral, morphological,
neurochemical, and brain metabolical features of the hMT1 transgenic mouse model of
DYT1 dystonia. The hMT1 model exhibits distinct motor, neurochemical, and
metabolical phenotypes that result from the cellular burden of mutant torsinA. Compared
to WT littermates, hMT1 mice showed prolonged traversal times on square and round
raised-beam tasks, more slips on the round raised-beam task, and increased hind-base
widths in foot-print analysis. No distinguishing cytoplasmic torsinA-positive inclusion
bodies or nuclear envelop abnormalities were noted in hMT1 mice. However, significant
increases of striatal DOPAC, HVA, and DA turnover (DOPAC/DA and HVA/DA) were
found in hMT1 mice. Brain metabolic abnormalities include a shift of metabolic demand
from structures of basal ganglia to olivocerebellar pathways in hMT1 mice compared to
controls. Our findings in DYT1 transgenic mice are compatible with previous
postmortem neurochemical studies of human DYT1 dystonia. Increased striatal DA
turnover in hMT1 mice suggests that the nigrostriatal pathway might be a site of
functional neuropathology in DYT1 dystonia. Increased activity in the direct and indirect
pathways, and the relatively attenuated metabolic demand in basal ganglia output regions,
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might be the primary consequence of a functional defect in the dopaminergic nigrostriatal
system in DYT1 mutation carriers. The increased metabolic demands in olivocerebellar
pathways (inferior olive, Purkinje cells, cerebellar nuclei) might be a compensatory
network response to increases thalamocortical activity. Alternatively, hypermetabolism
in olivocerebellar pathways might be largely independent of basal gangliathalamocortical dysfunction, in which case interactions between these two sensorimotor
networks contribute to the generation of a dystonic phenotype. In aggregate, our data
provide evidence that the hMT1 mouse might be used to study the systems and cellular
biology of torsinA, and to evaluate potential therapeutics for DYT1 dystonia.
4.2

DISCUSSION

Our findings of torsinA up-regulation after central and peripheral insults are
compatible with studies of developmental expression because up-regulation was also
noted during the period of neurogenesis and synaptic reorganization after forebrain
ischemia. In the hippocampus, an increased level of torsinA-IR was prominent in the
subgranular proliferative zone, which is the site of neuroblast proliferation after ischemia.
Increased torsinA-IR was also localized to cell populations in the SR, SO, and SLM in
regions of hippocampus (e.g., CA1) known to undergo neuron loss and synaptic
reorganization. Many of the cells in the CA1 region that showed overt up-regulation of
torsinA-IR were found to be GFAP-IR reactive astrocytes, somatostatin-IR interneurons,
and parvalbumin-IR interneurons. Glia may facilitate synaptic formation and synaptic
neurotransmitter release, and direct neuronal migration and neurite extension (Powell et
al., 1997; Araque et al., 1999; Grosche et al., 1999; Ventura and Harris, 1999; Riquelme
et al., 2002; Liu et al., 2004; Sobkowicz et al., 2006; Bystron et al., 2008). The upregulation of torsinA in reactive astrocytes might facilitate neuronal-network
reorganization by guidance of neuronal migration, neurite extension, or enwrapping many
pre- and post-synaptic terminals. Alternatively, torsinA might contribute to the
morphological and topological changes that reactive astrocytes must undergo in order to
facilitate synaptogenesis and network reorganization (Lepekhin et al., 2001; Witcher et
al., 2007). The surviving interneurons in the CA1 region also undergo significant
morphological changes, and might serve as substitute targets for Schaffer collateral and
other excitatory synaptic input after hippocampal ischemia (Arabadzisz and Freund,
1999). Accordingly, it is rational to postulate that torsinA might participate in structural
changes and/or transport of cell surface receptors in these hippocampal interneurons.
Via indirect cytoskeletal interactions, torsinA might also participate in the
formation of neurotransmitter vesicles and vesicular recycling (Augood et al., 2002;
Asanuma et al., 2005; Shashidharan et al., 2005; Dang et al., 2005; 2006; Balcioglu et al.,
2007; Grundmann et al., 2007). In support of this concent, Augood and colleagues
(2002) found a significantly increased DOPAC/ DA ratio, along with a trend toward
reduction in D1 and D2 receptor binding in the striatum in postmortem DYT1 dystonia
brains. Moreover, a variety of neurochemical alterations have been described in DYT1
knock-in, knock-down, and transgenic mice (Shashidharan et al., 2005; Dang et al., 2005;
2006; Balcioglu et al., 2007; Grundmann et al., 2007). Finally, Granata and co-workers
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(2008) found that synaptic vesicle recycling is regulated by torsinA expression.
Endogenous torsinA plays an important role to regulate the rate of synaptic vesicle
turnover. Importantly, overexpression of mutant torsinA significantly impaired the
process of vesicular endocytosis.
In line with previous human work and the recent publication by Granata et al.
(2008), our studies revealed significant increases of striatal DOPAC, HVA, and DA
turnover (DOPAC/DA and HVA/DA) in hMT1 mice. Increases in the DOPAC/DA and
HVA/DA ratios could be the manifestation of increased DA release, decreased DA
uptake due to abnormal functioning of the dopamine and/or vesicular monoamine
transporters or increased monoamine oxidase activity. In another study with hMT1 mice,
normal basal levels of striatal extracellular DA and decreased amphetamine-induced DA
release were identified (Balcioglu et al., 2007). Taken together, these findings suggest
that mutant torsinA disrupts nigrostriatal dopaminergic neurotransmission by interfering
with the normal biology of dopamine-containing vesicles and dopamine transporters at
the axon terminal.
In conclusion, the body of work included in this dissertation provides important
new insights into the systems biology of torsinA. The burden of mutant torsinA on
motor, neurochemical, morphological, and metabolic phenotypes was characterized in
mice and the role of normal torsinA in the central and peripheral nervous systems was
explored in perturbation models. Although our findings do not provide definitive roles
for wild-type and mutant torsinA in normal neural function and the pathobiology of
DTY1 dystonia, they do point out clear avenues for future study. In particular, the
neurochemical and metabolic abnormalities in hMT1 mice suggest that the metabolic
topography of the DYT1 carrier state might be due to a primary defect in nigrostriatal
neurotransmission. Furthermore, the appearance of dystonia might be due to
compensatory and maladaptive changes by the olivocerebellar network. Perturbation
models suggest that torsinA participates in reparative responses of the nervous system.
Thus, DYT1 dystonia appears to be a network disorder of reduced penetrance, which
could require an environmental perturbation to become clinically manifest. Given this
conceptualization, it may be useful to determine if perturbations such as transient
cerebral ischemia, hyperthermia or repetitive sensorimotor tasks can precipitate the
appearance of a dystonic phenotype in hMT1 mice.
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